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ABSTRACT
The Borrelia burgdorferi sensu lato (s.l.) complex contains species
carried by hard-shell ticks (Ixodes spp.) causing Lyme disease and related
non-pathogenic species. Relapsing fever Borrelia includes both tick-borne
(soft-shell, Ornithodoros spp.) and louse-borne species knowns to cause
relapsing fever. A subgroup includes relapsing fever spirochetes carried by
hard-shell ticks, including B. miyamotoi, an emerging pathogen. Despite
bordering high-risk counties in Minnesota, little attention has been given to
Lyme disease, B. burgdorferi, I. scapularis, or reservoirs in eastern North
Dakota. Reports of B. burgdorferi and I. scapularis in North Dakota, however,
prompted a more detailed examination. Through trapping Peromyscus and
Myodes, five B. burgdorferi populations were obtained. We confirmed the
presence of established, unique (nonclonal), and infectious B. burgdorferi
populations in eastern North Dakota. Species of the B. burgdorferi s.l.
complex possess two highly conserved hypothetical genes, bb0399 and
bbb28, containing one of the most common protein motifs, ankyrin-repeat
domains. The goal was to identify the function(s) of bb0399 and bbb28. Our
hypothesis was BB0399 is an essential DNA binding protein and BBB28 is
regulated by the Borrelia oxidative stress response regulator, BosR in
response to unknown stimuli. Exposing B. burgdorferi to tert-butyl
hydroperoxide increased transcription of bbb28 but not bb0399. Several
xvixvi
xvi

attempts to express recombinant BB0399 and BBB28 failed and the
functionsof bb0399 and bbb28 remain unknown. B. miyamotoi is an
emerging pathogen vectored by the same Ixodes spp. carrying and
transmitting B. burgdorferi. B. miyamotoi binds human factor H in vitro.
C57BL/6J Rag1-/- mice infected with a Japanese strain of B. miyamotoi,
FR64b, developed a chronic infection, while both 2-4 and 6-8 week-old wildtype C3H/HeN groups cleared B. miyamotoi. B. miyamotoi FR64b, normally
vectored by I. persulcatus, was acquired by North American I. scapularis and
maintained B. miyamotoi throughout the molting process from larvae to
nymph, suggesting unlike other relapsing fever Borrelia, B. miyamotoi is not
vector specific.

xviixvii
xvii

CHAPTER 1
AN INTRODUCTION TO BORRELIA BURGDORFERI
AND BORRELIA MIYAMOTOI
An array of viral, bacterial, and parasitic pathogens cause tick-borne
diseases. Tick-borne pathogens are transmitted through the bite of an
infected hard- or soft-shell tick belonging to four genera (Ixodes,
Dermacentor, Amblyomma, and Ornithodoros) (1–3). This group of diseases
include Lyme disease (Borrelia burgdorferi sensu lato), tick-borne relapsing
fever (Borrelia), anaplasmosis (Anaplasma phagocytophilum), rickettsiosis
(Rickettsia), babesiosis (Babesia), Powassan virus (Flavivirus), tick-borne
encephalitis virus (Flavivirus), Colorado tick fever (Coltivirus), and Heartland
virus (Phlebovirus) to name a few.
Borrelia
Species of the B. burgdorferi sensu lato (s.l.) complex are primarily
carried by Ixodes spp. (Ixodidae; hard shell). The s.l. complex includes nine
Borrelia spp. causing Lyme disease and approximately 11 non-pathogenic but
genetically similar Borrelia spp. (Table 1.1) (4–16). Borrelia spp. that cause
tick-borne relapsing fever (TBRF) are primarily carried by Ornithodoros spp.
(Argasidae; soft shell) (Table 1.1). Relapsing fever Borrelia are genetically
distinct from B. burgdorferi s.l. species but are genetically similar to each
other (Fig. 1.1).
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Table 1. 1.

Disease

Borrelia spp. confirmed to cause human disease and associated
vectors. NA – North America, Eu – Europe, As – Asia, Af – Africa.

Lyme disease

Tick-borne relapsing
fever

Causative agent(s)

Vector(s)

B. burgdorferi sensu
stricto (s.s.) (NA, Eu)
B. mayonii (NA)
B. bissettii (NA, Eu)
B. lusitaniae (Eu)
B. valaisiana (Eu)
B. afzelii (Eu, As)
B. garinii (Eu, As)
B. spielmanii (Eu, As)
B. bavariensis (Eu, As;
formerly B. garinii
OspA serotype 4)
B. hermsii (NA)
B. turicatae (NA)
B. parkeri (NA)
B. duttonii (Af)
B. crocidurae (Af)
B. hispanica (Eu, Af)
B. latyshevi (As)
B. persica (As, Af)

I.
I.
I.
I.

Hard tick-borne
relapsing fever

B. miyamotoi (NA, Eu,
As)

Louse-borne relapsing
fever

B. recurrentis (Af)

2

scapularis (NA)
pacificus (NA)
ricinus (Eu, As)
persulcatus (Eu, As)

O. hermsi (NA)
O. turicata (NA)
O. parkeri (NA)
O. moubata (Af)
O. erraticus; O. sonrai
(Af)
O. erraticus (Eu, Af)
O. tartakovski (As)
O. tholozani (As, Af)
I. scapularis
I. pacificus
I. ricinus
I. persulcatus
P. humanus humanus
(Af)

Figure 1. 1.

Maximum likelihood phylogenetic analysis of Borrelia flagellin.
B. burgdorferi s.l. species form a distinct, monophyletic clade;
relapsing fever Borrelia do not form a monophyletic clade,
however, they are separate from Lyme Borrelia species.
Values at nodes represent bootstrap values from 1000
replicates. Species of the B. burgdorferi s.l. complex (Lyme)
are shown in blue, relapsing fever Borrelia vectored or carried
by soft-shell ticks (Ornithodoros, Argas) are red, relapsing
fever Borrelia vectored by lice (Pediculus) is pink, relapsing
fever Borrelia vectored or carried by hard-shell ticks (Ixodes,
Amblyomma, Hyalomma, Rhipichephalus) are purple, and an
outgroup (Leptospira) is orange.
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4

The general classification for Borrelia currently holds as several Lyme
disease Borrelia are associated with hard-shell ticks and relapsing fever
Borrelia are associated with soft-shell ticks. However, five exceptions have
been documented. B. recurrentis is a louse-borne relapsing fever spirochete
presently endemic predominantly to sub-Saharan Africa. B. theileri is the
causative agent of bovine borreliosis and is transmitted by Rhipicephalus
microplus, a hard-shell tick that parasitizes livestock (17). B. lonestari and B.
turcica are genetically similar to relapsing fever borreliae and carried by the
hard-shell ticks Amblyomma americanum and Hyalomma aegyptium,
respectively (18, 19). The status of B. lonestari and B. turcica as an animal
or human pathogens is unknown. Finally, B. miyamotoi is a relapsing fever
spirochete vectored by the same Ixodes spp. transmitting species of the B.
burgdorferi s.l. complex (20, 21).
The Unusual Nature of B. burgdorferi S.L. Genetics
All known Borrelia spp. have unusual genomes compared to traditional
bacterial genomes, which consist of a circular chromosome. Species of the B.
burgdorferi s.l. complex have a highly fragmented genome comprised of a
linear chromosome (ca. 910 kilobases [kb]) and an array of linear and
circular plasmids (size from ca. 5 to 54 kb) (22). Twelve linear and nine
circular plasmids have been characterized from the B. burgdorferi s.s. B31
type strain, though the number and arrangement of plasmids vary by B.
burgdorferi s.l. strain (23, 24).

5

The chromosome mainly consists of essential genes (e.g. metabolism,
motility, replication) and appears to be stable (22, 25). Some essential genes
are found on plasmids thereby making those plasmids essential. The
presence of essential plasmids is in stark contrast to traditional bacterial
genomes where plasmids are usually unessential or extra-chromosomal
genetic elements. However, it should be noted the definition of “essential
plasmid” requires consideration of the environment and B. burgdorferi exists
in several environment types: in vivo in ticks (fed and unfed), in vivo in
numerous reservoirs and hosts, and in vitro in laboratory cultures. A plasmid
required for survival in a mouse may not be required for survival in a tick.
Prolonged in vitro passage results in strains losing plasmids (likely due to a
lack of selective pressure), which are required for establishing or maintaining
an infection in mice and/or ticks resulting in non-infectious isolates (26, 27).
The loss of plasmids, however, is not universal as some isolates do retain
plasmids and, thus, infectivity (28).
The genome, in terms of open reading frames (ORFs), is significantly
reduced compared to free-living bacteria but is on par with genome sizes of
other obligate parasitic bacteria such as Rickettsia and Chlamydia. B.
burgdorferi B31 currently has 1427 putative or known ORFs and 136
pseudogenes (22, 29). Of these 1427 ORFs, 588 (41.2%) are predicted
“hypothetical proteins,” or proteins meeting all the requirements to be
functional but lacking empirical data to demonstrate functionality. Very few
hypothetical proteins reside on the chromosome (26.4%) as many of these
are essential genes that have been assigned a function either through
6

identification of conserved domains and/or empirically. By comparison, 50%
of ORFs on 16 of the 21 plasmids found in B. burgdorferi B31 are
hypothetical proteins. Function and functionality of many of these will require
experimental data as only approximately 7.9% of predicted ORFs on B.
burgdorferi’s plasmids share homology to proteins from any genera outside
of Borrelia (30).
Relapsing Fever Borrelia Genetics is also Unusual
Relapsing fever species also share similar genetic traits though much
less is known about relapsing fever Borrelia as sequence data for most
species is still incomplete. As a result, much of what we know about
relapsing fever Borrelia comes from work with B. hermsii. Like species of the
B. burgdorferi s.l. complex, relapsing fever Borrelia have a linear
chromosome (ca. 923 kb) and several circular plasmids homologous to the B.
burgdorferi s.l. cp32 family (31, 32). Unlike B. burgdorferi s.l. spp., relapsing
fever Borrelia also have a linear megaplasmid (ca. 183 kb). B. hermsii HS1
(type strain) also has two circular plasmids (ca. 6.5 and 28.8 kb) and seven
linear plasmids (size from ca. 27 to 58 kb) (32).
Of the 1272 ORFs, 36.6% are predicted hypothetical proteins.
However, the vast majority of these hypothetical proteins are found on the
plasmids (ranges from linear plasmid B58 with 43.8% ORFs predicted as
hypothetical proteins to the megaplasmid with 87.9% hypothetical protein
ORFs). As with B. burgdorferi B31, the chromosome of B. hermsii HS1 has
the fewest hypothetical proteins (19.9%). Given the number of hypothetical
proteins predicted on B. hermsii plasmids, we presume a similarly small
7

percentage of predicted ORFs in B. hermsii lack homology to proteins from
genera outside Borrelia and will require empirical testing to determine the
function and functionality of many of these proteins.
Vectors and Associated Borrelia spp.
There are distinct morphological differences between Ixodes and
Ornithodoros ticks. Ixodes possess a hard plate on the back (dorsal scutum).
Ornithodoros, on the other hand, have leathery but soft skin. Ixodes have
mouthparts visible from dorsal and ventral perspectives, while Ornithodoros
mouthparts are only visible when observing the ventral side. In addition to
the gross anatomical differences, there are also behavioral differences
between Ixodes and Ornithodoros that may contribute to differences
observed between B. burgdorferi s.l. spp. and relapsing fever Borrelia.
Life Cycle of Ixodes and Enzootic Cycle of B. burgdorferi s.l.
Ixodes have a two-year, four-stage life cycle (Fig. 1.2). During year 1,
eggs are laid in spring and hatch to larvae in summer. Larvae will feed on
their first host, typically a small to medium mammal, rodent, or bird, some of
which are competent reservoirs for B. burgdorferi s.l. spp. Indeed, the larval
bloodmeal is a crucial point in the enzootic cycle of B. burgdorferi s.l., which
is not transovarially maintained in ticks. That is, an infected adult cannot
pass B. burgdorferi s.l. to the eggs. Ixodes can only acquire B. burgdorferi
s.l. by feeding on an infected reservoir. As a result, Lyme disease is not
considered be obtained through the bite of a larval Ixodes. After feeding,
replete Ixodes will detach and find refuge in a suitable habitat for the fall and
winter months. During year 2, larvae will molt to nymphs, emerge in the
8

Figure 1. 2.

Life cycle of Ixodes spp. and enzootic cycle of B. burgdorferi
s.l. Larvae (six legs) feed on small- to medium-sized animals,
providing the first opportunity for Ixodes to acquire B.
burgdorferi s.l. After feeding, larvae molt into nymphs (eight
legs) and feed on medium- to large-sized animals. A final
bloodmeal is consumed by adult females and pairs mate on a
medium- to large-sized animals. Females will drop from the
host to lay eggs.

spring, and seek its next bloodmeal. Nymphs will usually feed on small to
medium mammals, rodents, and birds. After detaching, nymphs will molt and
emerge as adults during the fall of year 2. Adults will find a medium to large
mammal, in particular, Odocoileus virginianus (white-tailed deer), a common
host for adults. Females, but not males, will take a bloodmeal and both will
mate. Males die shortly after mating, while females will drop from the host,
find suitable habitat, and lay eggs.
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Each life stage feeds once but Ixodes are considered generalist
feeders. Even though there are preferences for hosts (e.g. larvae tend to
feed on Peromyscus or white-footed mice more often than other hosts), as a
whole, Ixodes spp. feed on a variety of animals (33–45). Humans and
domestic animals can become hosts for all stages of Ixodes but are
considered dead-end hosts for B. burgdorferi s.l. as neither can sustain an
enzootic cycle. Species of the B. burgdorferi s.l. complex are not maintained
transovarially, a subject of debate for years. In retrospect, early reports of B.
burgdorferi being transovarially transmitted (46) were likely due to the
presence of B. miyamotoi, a relapsing fever spirochete transmitted by Ixodes
spp. discovered in 1995 (20). To become infected with B. burgdorferi s.l.,
ticks must feed on an infected animal and any stage can acquire B.
burgdorferi s.l. Larvae cannot transmit Lyme disease, thus the largest threat
for humans and domestic animals to acquire B. burgdorferi s.l. from ticks
come from unfed nymphs and adult females. Adult males can be infected,
however, since adult males do not typically partake in a bloodmeal, they
rarely transmit B. burgdorferi s.l. (47).
It is important to note the general perception of Ixodes, including host
preference by different life stages and even active periods, is based on the
most studied and largest endemic region for Lyme disease in North America,
Northeastern US. However, as we understand more about Lyme disease (i.e.
Ixodes, B. burgdorferi s.l., reservoirs, and hosts) in the upper Midwest,
southern US, California, Canada, Europe, and Asia, it is clear we need to view
Lyme disease as a regional disease, especially in terms of the maintenance of
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B. burgdorferi s.l., the chance to acquire Lyme disease, and public health
strategies for controlling Lyme disease.
P. leucopus (white-footed mouse) is a primary reservoir for B.
burgdorferi s.s. in the northeastern US and host for larval I. scapularis (48,
49, 49–52). In the upper Midwest, P. leucopus and P. maniculatus (deer
mouse) are both major reservoirs and hosts. However, in California, the list
of Ixodes hosts is long and several species are competent reservoirs for B.
burgdorferi s.l., including western grey squirrels (Sciurus griseus), California
kangaroo rats (Dipodomys californicus), and dusky-footed wood rats
(Neotoma fuscipes) (53–55). These species, not the Peromyscus spp.
present, represent the primary reservoirs for B. burgdorferi s.l. in California.
The primary hosts for larval and nymphal I. pacificus, however, are lizards,
particularly the western fence lizard (Sceloporus occidentalis) and the
southern alligator lizard (Elgaria multicarinata) (53). Both lizards are
refractory hosts for B. burgdorferi s.l. Likewise, in Europe and Asia, there
does not appear to be a single, predominant reservoir as a diverse population
of rodents, small and medium mammals, and birds serve as adequate B.
burgdorferi s.l. reservoirs and Ixodes hosts (56).
Life Cycle of Ornithodoros and Enzootic Cycle of Tick-Borne
Relapsing Fever (TBRF) Borrelia
Unlike Ixodes, Ornithodoros have a multi-year life cycle that is not
dictated by climate (Fig. 1.3). Eggs hatch into larvae, which feed on their
first host. Ornithodoros spp. are considered specialized feeders. Collectively,
Ornithodoros parasitize myriad mammals, rodents, and birds. Each species,
however, has preferred hosts and each individual Ornithodoros population
11

Figure 1. 3.

Life cycle of Ornithodoros spp. With the exception of
Ornithodoros eggs, each stage generally feeds upon the same
host species and is capable of acquiring and transmitting
relapsing fever Borrelia.

will be limited primarily to one host. After feeding, larvae detach and molt to
nymphs. Ornithodoros spp. have multiple nymphal stages. Each nymphal
stage will feed, detach, and molt to a new nymphal stage. After
approximately seven nymphal stages, Ornithodoros will molt to an adult. In
stark contrast to Ixodes, adult Ornithodoros can feed, without molting,
several times. Eventually, adults will mate and lay eggs.
Tick-borne relapsing fever (TBRF) Borrelia carried by Ornithodoros are
transovarially maintained. Thus, a tick can acquire Borrelia during any
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feeding (if the host is infected) or from an infected adult female. As with
Ixodes, humans and domestic animals can become incidental hosts for
Ornithodoros and dead-end hosts for relapsing fever Borrelia.
Habitats and Behavior of Ixodes and Ornithodoros
The geographic distribution of Ixodes spp. is governed by the
distribution of hosts and limited by temperature and humidity, with ticks
preferring environments with warm, humid summers and mild winters (57).
While off-host I. scapularis are highly susceptible to desiccation and low
temperature in laboratory experiments, established populations have been
found in regions that experience frigid and dry winters (38, 58–60). This
suggests that microclimates are invaluable for I. scapularis survival.
Deciduous and mixed forests provide leaf litter that maintains high relative
humidity and are regarded as the classic microhabitat for ticks. However,
several temperate biomes, including coniferous forests, grasslands, and
pastures also maintain microclimates that sustain Ixodes spp. (61–64) some
urban, peri-urban, and recreational environments support or are capable of
supporting Ixodes spp. and host populations (65–67).
Ixodes find hosts by questing. Ticks will crawl up vegetation, extend
their front legs, and wait for something, hopefully, a tasty bloodmeal and not
a researcher’s collection cloth, to brush against the vegetation. The tick will
attach and begin feeding. Desiccation is not a concern during feeding as ticks
absorb water from the bloodmeal. If a suitable bloodmeal is not obtained and
desiccation is a concern, Ixodes will crawl back to their humid habitat. Ixodes
are long-term, slow feeders, remaining attached to a host for approximately
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three to five days. Long attachment times, as well as the open environments
Ixodes inhabit, facilitates dispersal of a population, especially if Ixodes
attaches to a migrating mammal or bird.
Ornithodoros, in comparison, are found in more contained
environments such as animal dens, burrows, and nests. As a result,
Ornithodoros do not need to “hunt” for a bloodmeal and desiccation is less of
a concern. Ornithodoros are short-term, quick feeders, able to attach, feed,
and detach from a host in minutes to hours. Not surprisingly, dispersal of
Ornithodoros populations is quite limited.
Borrelia spp. Suitably Adapted to the Differences in Vector
B. burgdorferi s.l. are found in the tick midgut. When an infected
Ixodes feeds, Borrelia must sense a bloodmeal is occurring and begin
migrating from the midgut to the salivary glands and into the feeding pit
while shifting gene expression from tick-phase genes to mammalian-phase
genes. This process can take time for the slow-replicating microbe and works
quite well with Ixodes’ long attachment time.
A feeding nymph is the last chance B. burgdorferi s.l. has to ensure
survival of its genetic material since B. burgdorferi s.l. is not transovarially
maintained, Ixodes feed once per life stage, adult males do not feed, and
adult female Ixodes typically feed on deer, which are not competent
reservoirs for B. burgdorferi s.l. (68). TBRF Borrelia, on the other hand, are
found in the salivary glands of infected Ornithodoros, which allows for rapid
transmission from tick to host (69). With nymph and adult Ornithodoros
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capable of multiple feedings per life stage, TBRF Borrelia have ample
opportunities for transmission to and from a host.
An important and intriguing, but not yet understood difference
between B. burgdorferi s.l. and relapsing fever Borrelia involves vector
specificity, exclusivity, and complementarity. Vector specificity occurs when
serologically distinct bacterial strains have closely related vectors; vector
exclusivity occurs when one vector species carries one bacterial strain; and
vector complementarity occurs when one vector species carries multiple
bacterial strains (70, 71). An unspoken assumption is that species of the B.
burgdorferi s.l. complex are not vector specific or exclusive. That is, any
species of the B. burgdorferi s.l. complex is assumed to be able to establish
an infection in any Ixodes spp. While no experiments have shown exclusivity,
numerous surveys have cataloged the species of the B. burgdorferi s.l.
complex found in species of Ixodes. From these surveys and basic knowledge
of evolution, it appears some B. burgdorferi s.l. species are exclusive. For
example, B. bavariensis NT29, an Asian strain, is only found in I. persulcatus,
an Asian species, while European B. bavariensis strains are only found in the
European I. ricinus (72–74). Whether B. bavariensis demonstrates exclusivity
or simple geographic isolation remains unknown. An experiment attempting
to infect I. ricinus with an Asian strain of B. bavariensis is required. Other
species of the B. burgdorferi s.l. complex appear to be highly promiscuous.
B. burgdorferi s.s. has been found in I. scapularis, I. pacificus, I. ricinus, and
I. persulcatus. There may be strain restrictions, such that B. burgdorferi s.s.
B31 may not infect any species of Ixodes except I. scapularis. Still, the
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degree of specificity or exclusivity that may be present with B. burgdorferi
s.l. species pales in comparison to the exclusivity observed with relapsing
fever Borrelia. To date, all relapsing fever Borrelia identified are exclusive to
their respective vector, despite some significant overlap in geographic
distribution for some Ornithodoros spp. (75). That is, B. hermsii cannot
establish an infection in O. turicata; B. hermsii can only infect O. hermsi. The
mechanism by which this exclusivity occurs is still not understood.
Tick-Borne Spirochete Diseases
Lyme Disease
Diseases caused by Borrelia burgdorferi s.l., especially Lyme disease,
are relatively new diseases to be described. The first recorded account of
erythema migrans (EM), an inconsistent but distinguishing symptom of Lyme
disease, was made in Europe in 1909 by Dr. Arvid Afzelius (76). While
unconfirmed at the time, Dr. Afzelius suspected a tick bite (I. ricinus) was
involved in the development of EM. Lyme disease went unrecognized in the
US until an outbreak of juvenile rheumatoid arthritis occurred in Connecticut
in 1977 (77). By 1982, Dr. Willy Burgdorfer had isolated spirochetes from I.
scapularis (I. dammini) and shown antibodies to B. burgdorferi reacted
strongly with sera from Lyme disease patients (4).
Lyme disease is the top tick-borne disease reported to the Centers for
Disease Control and Prevention (CDC), with 38,069 confirmed and probable
cases reported in 2015. However, in 2012, the CDC released estimates
indicating the number of people infected with Lyme disease is underreported
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by about 10% and the actual number of cases in the US is closer to 300,000
(78).
Symptoms of Lyme disease in humans vary by species and shows a
distinct geographical pattern, though some symptoms are universal
(Table 1.2) (79, 80). In North America, where the primary etiological agent is
B. burgdorferi s.s., early stage Lyme disease (3-30 days post-infection) is
characterized by influenza-like symptoms (e.g. mild fever, malaise,
myalgia/arthralgia) and an associated, though not guaranteed, bullseye rash
(erythema migrans). Arthritis is a key symptom of late stage Lyme disease
(after 30 days post-infection). Lyme neuroborreliosis and carditis are also
late stage Lyme symptoms in the US, though the prevalence is much lower
compared to arthritis. In Europe, however, late-stage symptoms are more
diverse because there are more pathogenic Borrelia spp. present. B.
burgdorferi s.s. is found in Europe but is not a predominant strain. Thus,
Lyme arthritis does occur but at significantly lower rates compared to North
America. Acrodermatitis chronica atrophicans is a common late stage
symptom caused by B. afzelii. Neurological symptoms (Lyme
neuroborreliosis) characterized by numbness, Bell’s palsy, neck stiffness,
declining memory, and sleep disorders are also common late-stage
symptoms associated with B. bavariensis infection. Infection with B.
burgdorferi s.l. is not self-resolving and does require treatment, usually a
course of ceftriaxone or doxycycline (81).
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Table 1. 2.

Disease
Lyme disease

Clinical symptoms of human Borrelia diseases.

Tick-borne
relapsing fever

Hard tickborne
relapsing
fever/Borrelia
miyamotoi
disease

Louse-borne
relapsing fever

Clinical symptom(s)
Symptom onset after exposure: early stage generally 3-30 days
–Influenza-like (e.g. mild fever, malaise, myalgia/arthralgia; B.
burgdorferi s.s.)
–Erythema migrans (B. burgdorferi s.s., B. afzelii)
–Symptom onset after exposure: late stage generally > 30 days
–Arthritis
–Acrodermatitis chronica atrophicans (B. afzelii)
–Neurological (Lyme neuroborreliosis, e.g. numbness, Bell’s
palsy, stiffness of neck, declining memory, sleep disorders; B.
burgdorferi s.s., B. bavariensis)
Symptom onset: ca. 7 days
–Influenza-like
–Recurring high fever
–Headache
–Myalgia
–Arthritis
Approximately 3-10 febrile episodes (relapses) occur; mortality
rates are variable but generally less than 5%
Symptom onset after exposure: ca. 15 days (82)
–Influenza-like
–Most common:
–Fever
–Malaise
–Headache
–Chills
–Arthritis/arthralgia
–Meningoencephalitis (immunocompromised patients)
Rare (less than 10% of patients):
–Rash/Erythema migrans
–Gastrointestinal (e.g. vomiting, nausea, diarrhea)
–Cardiac/respiratory (shortness of breath)
–Neurological (e.g. dizziness, confusion)
–Stiffness of neck
Symptom onset after exposure: ca. 4-8 days
–Recurring high fever
–Malaise
–Headache
–Chills
–Meningism
–Myalgia
–Nausea
–Vomiting
Approximately 3-5 relapses occur; mortality rate varies greatly
(30-70% without treatment during outbreaks)
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Tick-Borne Relapsing Fever
Unlike Lyme disease, TBRF is not nationally reportable. TBRF is,
however, reportable in 11 endemic states (California, Washington, Colorado,
Idaho, Nevada, Oregon, Arizona, Texas, New Mexico, Montana, Utah,
Wyoming) and one bordering state (North Dakota, note no TBRF cases have
been reported in North Dakota). Approximately 70% of TBRF cases are
reported in California, Washington, and Colorado. Data collected from these
12 states between 1990 and 2011 indicate 504 cases of TBRF have been
reported (83).
There is less diversity in the symptoms of TBRF in humans. Influenzalike symptoms appear approximately seven days post-infection (Table 1.2).
The defining characteristic of TBRF is recurring spirochetemia events leading
to febrile episodes. TBRF can be fatal (mortality rate is generally less than
5%) but is usually self-resolving after approximately three to ten recurring
febrile episodes. Louse-borne relapsing fever (B. recurrentis) has similar
symptoms though approximately three to five febrile episodes occur and
mortality can be much higher (30-70% without treatment during outbreaks).
Hard Tick-Borne Relapsing Fever or
Borrelia miyamotoi Disease
Hard tick-borne relapsing fever (HTBRF) or Borrelia miyamotoi disease
(BMD) is an emerging disease first described in 2011 (82). Numerous cases
have been documented for Lyme disease and TBRF allowing for a defined set
of typical symptoms. Much of the data currently available for B. miyamotoi
infections come from retrospective serological analyses of banked patient
samples, which provide valuable epidemiological information but can lack the
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detailed patient history or clinical aspects required to sufficiently define a
disease. Two large studies in Russia (82) and the US (84) suggest HTBRF is a
disease similar to TBRF.
The Russian patients described by Platonov et al (82) reported tick
bites, developed moderate or severe disease, and were hospitalized as a
precautionary measure against more severe tick-borne diseases, particularly
viral tick-bone encephalitis. Forty-six patients were classified as having a
confirmed B. miyamotoi infection with no detected current B. burgdorferi s.l.
coinfection by PCR though all patient sera reacted with whole cell lysates of
B. burgdorferi s.s., B. afzelii, and B. garinii. The most common symptoms
were fever, headache, and malaise or fatigue (Table 1.3). Five patients
reported recurrent fever with an average duration of 3.4 days, and 9 days
between relapses, a similar timeline for TBRF. All patients were successfully
treated with ceftriaxone or doxycycline.
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Table 1. 3.

Comparison of B. miyamotoi symptoms reported from US (84) and
Russian (82) patients
Symptom
US (n = 51)
Russia (n = 46)
Fever, chills
96%
96%, 35% a
b
Headache
96%
89%
Myalgia
84%
59%
Arthralgia
76%
28%
Malaise/fatigue
82%
98%
Rash/EM c
8%
9%
Gastrointestinal d
6%
30% (nausea)
7% (vomiting)
e
Respiratory
6%
na f
Neurological (dizziness,
8%
na
confusion, vertigo)
Stiff neck
na
2%
a
Fever and chills were reported in separate categories
b
Authors noted in most patients the headaches were severe
c
US patients were described as having a rash. Russian patients were noted for
having a single erythema migrans
d
For US patients, GI symptoms included nausea, abdominal pain, diarrhea,
anorexia. For Russian patients, GI symptoms included nausea and vomiting
e
Labored breathing or shortness of breath
f
Not reported

In the US, 97 of 11.515 patient samples submitted by clinical
laboratories for tick-borne disease analysis were PCR-positive for B.
miyamotoi (84). Patients with known or suspected B. burgdorferi s.s.
coinfection or a history of Lyme disease were omitted from further analysis.
Fever, headache, and malaise were commonly reported among US patients
with two patients reporting recurrent fever (Table 1.2). The duration of
febrile episodes and the time between relapses were not reported.
Spirochetemia was noted in US patients but either not reported or
documented in Russian patients. Strikingly, a rash or single erythema
migrans of unknown origin, a symptom associated with B. burgdorferi s.l.
infections, was reported in 8 and 9% of US and Russian patients,
respectively.
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In addition, some symptoms were different between US and Russia
patients, which suggest clinical manifestations vary by B. miyamotoi strain,
similar to that seen with B. burgdorferi s.l. strains (Table 1.2) (80).
Arthralgia was more common in US (76%) compared to Russian patients
(28%), and leukopenia, thrombocytopenia, and elevated liver enzymes were
found in some US patients but none of the Russian patients. These
differences may be explained by genetic differences between American and
Asian type B. miyamotoi. Genetic analyses of B. miyamotoi isolates reveal
heterogeneity between, and a high degree of homology among, strains from
the US (American types; I. scapularis, I. pacificus), Europe (European type;
I. ricinus), and Asia (Asian type; I. persulcatus) (85, 86).
Detailed case reports are currently available for nine patients in the
US, Europe, and Japan. For immunocompetent patients, symptoms were
similar to those observed in the aforementioned studies (e.g. fever,
headache, malaise) (87–91). One US patient did not seek treatment,
providing additional evidence that B. miyamotoi can result in recurrent fever
and be self-resolving, similar to other relapsing fever infections (92, 93). This
patient experienced two episodes of fever separated by three weeks,
significantly longer than in other B. miyamotoi or relapsing fever patients,
with each episode lasting 4-5 days, on par with B. miyamotoi or relapsing
fever patients.
The pathology of B. miyamotoi infection is dramatically different in
immunocompromised patients, specifically, those treated for non-Hodgkin’s
lymphoma (NHL) treated with rituximab. Two patients treated with rituximab
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for NHL, one from the US (94) and one from the Netherlands (95), with
reported recent tick bites developed meningoencephalitis. Motile spirochetes
were detected in cerebral spinal fluid in both cases. Interestingly, glpQ
(glyphosphodiesterase; among Borrelia, glpQ is unique to relapsing fever
Borrelia) was amplified and sequenced from both patient’s samples yet no
anti-GlpQ antibodies were detected in the blood or cerebral spinal fluid of the
European patient. IgM against B. burgdorferi was negative for both patients.
Neither patient reported any of the commonly associated symptoms of a B.
miyamotoi infection (e.g. fever, headache, myalgia, malaise). Instead, both
patients exhibited neurological symptoms (cognitive processing defects,
disturbed gait). A third patient from Germany, also with treated with
rituximab for NHL developed Lyme neuroborreliosis-like symptoms
(dizziness, vomiting, and headache) (96).
General Immune Responses and
How Borrelia Deal with Them
To establish long-term infection in rodents and mammals (late or
disseminated phase of Lyme disease in humans), B. burgdorferi s.l. migrates
to various sites, such as joints, skin, heart, and bladder (97–105). These
sites offer much protection from cells of the immune system, however,
Borrelia has not unlocked the mysteries of teleportation. As a result, B.
burgdorferi s.l. must migrate to these sites from the inoculation site (tick
bite) and will encounter immune cells producing complement and a humoral
immune response. Ixodes saliva contains adaptive and innate
immunomodulatory and anti-complement proteins that offer some protection
for B. burgdorferi s.l. (106–113). B. burgdorferi s.l. possess a handful of anti23

complement proteins with the best understood being factor H binding
proteins (114–117). The ability to bind and neutralize complement through
binding factor H is vital for B. burgdorferi s.l. to establish infection (114).
Relapsing fever Borrelia migrate from the inoculation site to the blood
where they remain until cleared by the immune system. Ornithodoros
salivary gland extracts also possess proteins that inhibit the host immune
response (118–121). Despite possessing factor H binding proteins,
complement is not an effective method for relapsing fever Borrelia to
establish infection, meaning complement is not the primary mechanism to
clear relapsing fever Borrelia (122, 123). Instead, the primary mechanism for
clearance is an humoral response.
The humoral response is important for controlling and preventing both
B. burgdorferi s.l. and relapsing fever Borrelia infections (124–131). Indeed,
these responses form the basis of an intense research effort for effective
Lyme vaccines. Fortunately for Borrelia, they are quite adept at evading the
host humoral response primarily through variation of surface-exposed
proteins. Lyme disease Borrelia possess outer surface proteins (Osps) and
variable membrane protein-like (Vls) proteins, while relapsing fever Borrelia
possess variable membrane proteins (Vmps; include variable large and
variable small proteins) (132–136).
Osps and VlsE of Lyme Borrelia
The outer surface proteins (Osps), particularly OspC, are one of the
most studied groups of Borrelia proteins (117, 137, 138). ErpA (OspE) and
OspF are factor H-binding proteins. OspA, a protein predominantly involved
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in uptake and survival in tick, is immunogenic and able to block antibody
binding to another surface-exposed protein, P66 (139, 140). OspC has
diverse roles, many of which are essential for transmission from Ixodes and
establishing infection in mammals (141–148). These studies were key in
demonstrating that ospC is upregulated during the early stages of infection,
downregulated after infection has been established, and deleting or
overexpressing ospC results in spirochetes that are quickly cleared from a
host.
A handful of immune evasion functions have been identified for OspC.
OspC protects Borrelia by binding Salp15, an Ixodes salivary protein. OspC
also prevents phagocytosis by macrophages (148). In addition, several OspC
types have been identified and correlated with a strains ability to establish
infection in hosts and reservoirs (98, 99, 149–152). However, as each Osp is
present as a single-copy locus, genetic variation is seen at the population
level. That is, outside of random mutation or horizontal gene transfer events,
a single spirochete cannot produce different OspC types in situ.
In contrast, the Vls (Vmp-like sequences) system can change the
expressed surface antigen in situ (Fig. 1.4). Antigenic recombination of VlsE
is important in maintaining infection in mammals and helps Lyme Borrelia
evade the humoral immune response (153–166). The Vls system is
composed of approximately 16 vls cassettes (the exact number varies by
strain) and one expression locus, vlsE. All of the identified vls cassettes are
located on the same plasmid (lp28-1) in close proximity to but in the
opposite direction of vlsE. Expression at vlsE occurs through the random
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Figure 1. 4.

Antigenic variation of Lyme borreliae VlsE and relapsing fever
borreliae Vmp systems. (A) VlsE. The expression locus (vlsE)
is located near the telomere of linear plasmid (lp) 28-1 (blue
or green arrow, promoter is indicated by a black arrow).
Silent vls cassettes are located upstream and in the opposite
orientation of vlsE. Antigenic variation occurs through the
random and sequential insertion of silent cassette fragments
(labeled 1, 2, and 3). (B) vlp (pink arrows) and vsp (purple
arrows) cassettes are located throughout the genome on
lp28-1, 28-2, 28-3, 28-4, and 32-1. The expression locus
(blue or green arrow, promoter is indicated by a black arrow)
is found on lp28-1 near the telomere (open oval). Changing
the expressed Vmp cassette is achieved through deletion of
the current cassette (blue arrow) followed by insertion of a
copy of a new cassette (green arrow via recombination
events) resulting in a change in the expressed Vmp on the
surface of the bacterium (denoted by blue or green triangles,
respectively). Grey arrows indicate non-Vmp ORFs; tan
arrows indicate downstream homology sequences (DHS,
sequences found throughout the genome and required for
mapping recombination events at the Vmp expression locus).
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recombination of segments of multiple vls cassettes rather than
recombination of an entire, single vls cassette. Thus, recombination events
result in thousands of unique VlsE variants, all approximately 36-kD.
Vmps of Relapsing Fever Borrelia
Vmps, a system similar to Vls, are one of the best characterized
immune evasion mechanisms (132, 167–170). B. hermsii has approximately
60 unique and promoterless vmp cassettes (i.e. silent cassettes) scattered
throughout its genome and one promoter-driven vmp expression locus (Fig.
1.4). A single vmp cassette is expressed when the entire cassette is moved
to the expression locus.
The majority of spirochetes are cleared from the host through specific
anti-Vmp IgM antibodies raised against the predominantly expressed Vmps,
which results in a significant decrease in spirochete load (from approximately
105-107 spirochetes/mL to < 104 spirochetes/mL). The remaining spirochetes
consist of a small population expressing different cassettes. Since the host
has not raised a strong antibody response to these non-dominantly
expressed Vmps, this minority population of spirochetes can proliferate to
high concentrations until an antibody response is mounted and the majority
of spirochetes are once again cleared. This cycle of vmp conversion, peaking
spirochete loads, and antibody-mediated clearing repeats a minimum of two
times resulting in the characteristic symptoms of a relapsing fever illness.
Mechanisms of Immune Evasion by B. miyamotoi
Given the genetic similarity of B. miyamotoi to relapsing fever
spirochetes, it is likely B. miyamotoi utilizes some homologous mechanisms
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to evade host immune responses. While B. miyamotoi is resistant to
complement in vitro (171, 172), complement inactivation is not required for
relapsing fever spirochetes to establish infection. OspE homologues have
been identified in B. miyamotoi FR64b (isolated from the blood of A.
argenteus) however, McDowell et al. were unable to demonstrate binding of
factor H (115). We observed factor H binding using whole-cell B. miyamotoi
FR64b lysates and Röttgerding et al. (173) showed B. miyamotoi HT31
expresses a functional FH-binding protein. CbiA, which binds FH in vitro.
While the role of FH-binding remains unknown, it appears, as is the case for
relapsing fever spirochetes, inactivation of complement may not be required
to resolve spirochetemia during infection with B. miyamotoi (126, 174).
Instead, B. miyamotoi likely utilizes a Vmp system (175, 176), which
relies on antigenic variation of Vmp. C3H/HeN mice infected with B.
miyamotoi LB-2001 produced anti-Vsp1 IgM and IgG antibodies that were
effective in clearing the initial spirochetemic peak of B. miyamotoi from SCID
mice (176). Despite this clearing, a second spirochetemic relapse occurred.
Analyses of the secondary B. miyamotoi population revealed expression of
vlpC2, not vsp1, as would be expected in the case of antigenic variation.
They also noted vlpC2 was present in the initial B. miyamotoi population in a
much lower prevalence compared to vsp1.
Problem
B. burgdorferi s.l. has had a significant impact on human health of
both immunocompetent and immunocompromised individuals and Lyme
disease is expected, at a minimum, to maintain its status as a public health
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threat. The effect B. miyamotoi has had and will have remains unknown,
though there is a clear impact on immunocompromised individuals that is
cause for concern.
Despite both B. burgdorferi s.l. and B. miyamotoi being demonstrated
human pathogens, several essential questions remain unanswered. Both
possess uncharacterized genes, which prevent a comprehensive
understanding of the physiology, pathogenesis, prevention, and treatment of
Lyme disease and HTBRF. While we have a decent understanding of the
enzootic maintenance of B. burgdorferi s.s. in the northeastern US, we are
still filling in large holes in the enzootic maintenance of B. burgdorferi s.l. in
other areas of North America. There are more unknowns regarding the
enzootic maintenance of B. miyamotoi.
During my graduate career, I attempted to address some basic
questions regarding B. burgdorferi s.s. and B. miyamotoi. Specifically, 1. The
enzootic maintenance of B. burgdorferi in North Dakota, 2. The physiological
role of proteins in the survival and pathogenesis of B. burgdorferi, and 3. The
enzootic maintenance of B. miyamotoi.
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CHAPTER 2
THE WESTERN PROGRESSION OF LYME DISEASE:
INFECTIOUS AND NON-CLONAL BORRELIA BURGDORFERI
SENSU LATO POPULATIONS IN GRAND FORKS COUNTY,
NORTH DAKOTA
Introduction
Eastern North Dakota borders some Minnesota counties (i.e., Kittson,
Marshall, Polk, and Norman) where the risk of contracting the tick-borne
diseases Lyme disease or human granulocytic anaplasmosis is moderate to
high based on confirmed human cases (177, 178), the abundance of Borrelia
burgdorferi-positive Ixodes scapularis (179), and the density of nymphal I.
scapularis (177). Despite this close geographical proximity, there has been a
paucity of studies on the migration of I. scapularis or B. burgdorferi into
North Dakota (38). Eastern North Dakota is classified as a transition zone for
Lyme disease based on studies investigating the expansion of I. scapularis
and B. burgdorferi in the Midwest (179). However, in 2011, the North Dakota
Department of Health reported results of a 2010 survey showing established
I. scapularis populations in six eastern North Dakota counties, including
Grand Forks county (180). In addition, the pathogens Anaplasma
phagocytophilum, Babesia sp., and B. burgdorferi were detected in I.
scapularis via PCR (180).
Surveillance of I. scapularis has shown an increase in its geographic
distribution (181–183), which has been accompanied by a concomitant
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increase in the distribution of confirmed Lyme disease cases (184). The
primary causative agents of Lyme disease differ between the US and Europe
with B. burgdorferi sensu stricto being the primary agent in the US and B.
afzelli and B. garinii being the primary agents in Europe (185, 186). While it
is generally accepted that B. burgdorferi s.l. is the sole cause of Lyme
disease in the US, there is increasing evidence that other members of the B.
burgdorferi sensu lato complex, a group consisting of approximately 20
closely related species, could also cause Lyme disease in the US (4–16). For
example, B. bissettii, has been identified in DNA isolated from human sera
samples in California residents by sequence analysis of p66; however, it has
not been clearly associated with Lyme disease in the US because many of the
samples that were positive for B. bissettii were also positive for
B. burgdorferi (187). It has been demonstrated, however, to be associated
with Lyme disease in Europe (185, 188) and has been shown to be infectious
and pathogenic in a mouse model (189). B. americana, found in I. pacificus
and I. minor, is predominantly found in California and South Carolina and has
not yet been associated with Lyme disease in humans (185), but antibodies
to B. americana have reportedly been detected in blood from Lyme disease
patients (190). These data underscore the need to correctly identify newly
isolated Borrelia species in order to assess their potential contribution to
human disease.
Several schemes have emerged to classify presumptive Lyme disease
Borrelia. One is based on outer surface protein C (OspC), a protein expressed
only during transmission from vector to host (141, 144) that is required for
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B. burgdorferi to infect mammals (143, 146). While ospC is highly
polymorphic, many groups or types have been described (98, 149). OspC
types are commonly used to determine a strains ability to cause
disseminated infections in humans (98, 191, 192). OspC groups A-U have
been identified (98, 149) with A-O, T, and U found in North America (98, 99,
191). Groups A, B, I, K, and N have been found most commonly associated
with disseminated infections in humans (98, 152, 193). Groups C, D, E, F, G,
H, and M have also been found capable of causing disseminated infection in
humans, although the occurrence of infection with these types is much lower
(151, 193). B. burgdorferi small mammal reservoirs have been found to
carry specific OspC types (150). For example, it has previously been shown
Peromyscus leucopus (white-footed mouse) tested positive for groups A, B,
D, F, G, I, and K, while Tamias striatus (eastern chipmunk) tested positive
for groups A, D, F, G, I, K, T, and U (150).
Antigenic outer surface proteins (e.g., OspC) are highly variable and
there are indications they are subject to horizontal gene transfer (194–196),
which make them less than ideal candidates for evaluating evolutionary
history and geographical relationships of B. burgdorferi strains. Multilocus
sequence typing (MLST) schemes have been developed that have proven to
be the most reliable method for determining the history and relationship
within many bacterial genera and species, including B. burgdorferi s.l. strains
(197, 198). MLST is based on the analysis of housekeeping genes, which are
under strong pressure to minimize large-scale mutation events, such as
those events seen in outer surface proteins. The B. burgdorferi MLST scheme
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utilizes eight housekeeping genes: clpA, clpX, nifS, pepX, pyrG, rplB, recG,
and uvrA (198). Each gene is assigned an allele number based on the
sequence identity to previously submitted alleles. The profile produced from
all eight loci corresponds to a sequence type (ST), which can be used to
compare strains to determine evolutionary history and relationships.
With the discovery of I. scapularis and B. burgdorferi in eastern North
Dakota, we sought to characterize previously unidentified spirochete cultures
obtained from five hearts of Peromyscus spp. (deer mice) and Myodes
gapperi (Southern red-backed vole) trapped in the Turtle and Forest River
areas of eastern North Dakota. All five small mammals harbored unique or
non-clonal populations of spirochetes determined to be B. burgdorferi s.l. The
presence of non-clonal populations is significant as it indicates the B.
burgdorferi populations present in eastern North Dakota are not the result of
a recent or single migration event. Two of the five small mammals were
carrying at least two different OspC types. OspC typing showed the infectious
B. burgdorferi types A, B, E, F, and I are disproportionately represented in
our samples. However, one isolate typed to the non-infectious group L and
one typed to none of the previously described groups. B. burgdorferi M3
(ospC group B) was obtained from M. gapperi at Forest River and predicted
to be a highly infectious isolate. Using this isolate, we determined B.
burgdorferi M3 is infectious in laboratory mice via both artificial and natural
routes of exposure, culturable from mouse tissues, and survives I. scapularis
molting. These data confirm B. burgdorferi is present in eastern North Dakota
and is infectious and transmissible in a laboratory model.
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Materials and Methods
Animal Care and Use
Infection experiments were performed per a University of North
Dakota Institutional Animal Care and Use (UND IACUC) approved protocol
#1101-2 at the University of North Dakota Center for Biomedical Research.
Four to six week-old BALB/c mice (Harlan; Madison, WI) were cared for in
accordance with the Association for Assessment and Accreditation of
Laboratory Animal Care guidelines (Animal Welfare Assurance A3917-01) and
the National Research Council of the National Academics Guide for the Care
and Use of Laboratory Animals (8th edition). Wild rodents were collected,
euthanized, and necropsied in the field as described in the UND IACUC
approved protocol #1304-3. All efforts were made to minimize animal
suffering.
Sample Collection and Culturing Spirochetes
Live trapping of rodents was conducted during June and July 2012 in
the two largest forested areas within an otherwise agricultural landscape in
Grand Forks County: i.e., Turtle River State Park (47.94oN, -97.50oW; ca.
254 hectares) and Forest River Biological Station and Wildlife Management
Area (48.17oN, -97.66oW; ca 349 hectares). Sherman live traps (H.B.
Sherman Traps; Tallahassee, Florida) were baited with peanut butter and
oatmeal, supplied with cotton bedding, set in the evening, and recovered in
the morning. Captured mammals were identified as M. gapperi and
Peromyscus spp. based on morphological characteristics. This method makes
it difficult to identify Peromyscus species in the field; thus, Peromyscus were
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identified only to the genus level. However, all of the Peromyscus in this
study were trapped deep in deciduous forests, a preferred habitat for P.
leucopus, while P. maniculatus prefer more open terrain and/or coniferous
forest, strongly suggesting the captured Peromyscus were P. leucopus
(Robert Seabloom, personal communication; (199). Peromyscus spp. and M.
gapperi were euthanized with isoflurane, necropsied, and hearts immediately
inoculated into modified Barbour-Stoenner-Kelly (BSK-II) medium containing
6% rabbit serum and 50 µg/mL rifampin (200). Surgical tools were sterilized
with 95-99% ethanol prior to each necropsy to prevent possible crosscontamination between animals. Three days later, uncontaminated cultures
were blind passed into modified BSK-II with 6% rabbit serum without
rifampin, incubated for three additional days, then examined for spirochetes
via dark field microscopy.
Amplification and Sequencing of ospA, ospC, flaB,
16S, 16S-ile tRNA IGS, and p66
ospA, ospC, p66, and the 16S-ile tRNA IGS were obtained using
amplification conditions previously described (201), except the annealing
temperature was adjusted to 48°C (see Table 2.1 for primers used). 16S and
flaB were amplified using the following conditions: 1 cycle 94°C for 5 min, 40
cycles of 94°C for 30 sec, 50°C for 30 sec, 68°C for 1 min, 1 cycle 72°C for 5
min. Sequencing was performed at Davis Sequencing (Davis, California).
Chromatograms were visually inspected then the forward (coding) and
reverse (template) strand sequences were aligned to obtain a doublestranded consensus sequence. 16S sequences were queried using the
Ribosomal Database Project’s Sequence Match (Seqmatch) program (202)
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Table 2. 1.

Primer sequences used in this study and the predicted
amplicon sizes. Primers obtained from other sources are
indicated after primer name.

Primer name

.

Sequence (5’-3’)

Predicted
amplicon size in
nucleotidesa
136 nt

16S For
GGT CAA GAC TGA CGC TGA GTC A
16S Rev
GGC GGC ACA CTT AAC ACG TTA G
flaB For
GGG TCT CAA GCG TCT TGG
139 nt
flaB Rev
GAA CCG GTG CAG CCT GAG
ospA For
ATG AAA AAA TAT TTA TTG GGA ATA GG 829 nt
ospA Rev
ATT CTC CTT ATT TTA AAG CG
ospC For (200)
ATG AAA AAG AAT ACA TTA AGT GC
638 nt
ospC Rev
CTT AAT TAA GGT TTT TTT GG
p66 For
GAT TTT TCT ATA TTT GGA CAC AT
755 nt
p66 Rev
TGT AAA TCT TAT TAG TTT TTC AAG
16S IGS For
AGT GCG GCT GGA TCA CCT CC
950 nt
ileT IGS Rev
GTC TGA TAA ACC TGA GGT CGG A
(200)
nid1 For
CCA GCC ACA GAA TAC CAT CC
153 nt
nid1 Rev
GGA CAT ACT CTG CTG CCA TC
recA For
GTG GAT CTA TTG TAT TAG ATG AGG CT 171 nt
recA Rev
GCC AAA GTT CTG CAA CAT TAA CAC CT
I. scap 16S For
CGG TCT GAA CTC AGA TCA AG
300 nt
I. scap 16S Rev
GGG ACA AGA AGA CCC TAT C
MLST primers for amplification and sequencing from
borrelia.mlst.net/misc/info.asp
clpA For
AAA GAT AGA TTT CTT CCA GAC
982 nt
clpA Rev
GAA TTT CAT CTA TTA AAA GCT TTC
clpX For
GCT GCA GAG ATG AAT GTG CC
884 nt
clpX Rev
GAT TGA TTT CAT ATA ACT CTT TTG
nifS For
ATG GAT TTC AAA CAA ATA AAA AG
1049 nt
nifS Rev
GAT ATT ATT GAA TTT CTT TTA AG
pepX For
ACA GAG ACT TAA GCT TAG CAG
811 nt
pepX Rev
GTT CCA ATG TCA ATA GTT TC
pyrG For
GAT TGC AAG TTC TGA GAA TA
801 nt
pyrG Rec
CAA ACA TTA CGA GCA AAT TC
recG For
CCC TTG TTG CCT TGC TTT C
805 nt
recG Rev
GAA AGT CCA AAA CGC TCA G
rplB For
TGG GTA TTA AGA CTT ATA AGC
760 nt
rplB Rev
GCT GTC CCC AAG GAG ACA
uvrA For
GAA ATT TTA AAG GAA ATT AAA AGT AG 911 nt
uvrA Rev
CAA GGA ACA AAA ACA TCT GG
a
Predicted amplicon size was determined using the following respective accession
versions: B. burgdorferi B31 AE000783.1 (chromosome), AE000790.2 (lp54),
AE000792.1 (cp26); Mouse: NC_000079.6 (nid1).
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and the Nucleotide Collection (nr/nt) BLAST database
(blast.ncbi.nlm.nih.gov) to obtain genus and species identifications. flaB,
ospA, ospC, p66, and the IGS region nucleotide sequences were queried
using BLAST.
NCBI Nuccore and BLAST Database Searches
Sequences were obtained by searching the NCBI nuccore database
(www.ncbi.nlm.nih.gov/nuccore) using the following terms: Borrelia + p66;
Borrelia + ospC; Borrelia + “outer surface protein C;” Borrelia + ospA;
Borrelia + “outer surface protein A;” Borrelia + “intergenic spacer region;”
Borrelia + IGS; Borrelia + 16S + 23S + IGS; Borrelia + 16S + 23S +
“intergenic spacer region.” A search was performed in the non-redundant
protein sequence (nr) BLAST database using the complete B. burgdorferi B31
protein sequences for p66 (chromosome accession: NC_001318.1), OspC
(cp26 accession: NC_001903.1), and OspA (lp54 accession: NC_001857.2).
Alignments and Phylogeny
Sequences for ospA, ospC, p66, and the IGS regions from eastern
North Dakota isolates were aligned along with BLAST and NCBI database
sequences in ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/). The shaded
alignment was generated using BoxShade (ExPASy,
www.ch.embnet.org/software/BOX_form.html). Duplicate sequences
(identified as the same species and found to be 100% identical) were
represented in the analyses by a single sequence. Sequences obtained from
BLAST were included in analyses if the query coverage was greater than
90%. Obtained sequences were manually trimmed to conserved regions
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aligning to the shortest sequence obtained for the eastern North Dakota
isolates. Trimmed sequences meeting the above criteria were then used in
phylogenetic analyses. For OspA and OspC, a subset of sequences from each
clade was chosen to create representative phylogenetic trees. Final
phylogenetic analyses for OspA, OspC, and p66 were performed using the
PHYLIP programs SeqBoot, Proml, and Consense (Version 3.695,
http://evolution.genetics.washington.edu/phylip/). Briefly, sequence files
were put into SeqBoot and analyzed with1000 bootstrap replicates. The
SeqBoot output file was analyzed in Proml using the Jones-Taylor-Thornton
model with multiple data sets, slower analysis, a random number seed of 9,
data sets jumbled 5 times, and an outgroup root when appropriate. The
resulting file was input into Consense to obtain a single consensus tree using
the majority rule (extended) consensus type and treated as rooted when
appropriate. DNA trees were created using Dnaml in PHYLIP. Trees were
visualized using FigTree (Version 1.4,
http://tree.bio.edu.ac.uk/software/figtree) and labeled using Adobe
Illustrator CS3 (San Jose, California).
OspC Typing
To sequence ospC from mixed populations, PCR products for ospC
from samples M6, M7, and M9 were gel purified and cloned into E. coli using
the pCR2.1 TOPO TA Cloning Kit per the manufacturer’s instructions (Life
Technologies; Carlsbad, California). Plasmids were purified using the QIAGEN
Plasmid Mini Prep kit (Valencia, California) and sequenced at Davis
Sequencing. OspC amino acid sequences for previously typed isolates
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(98, 99) were obtained from NCBI. Nucleotide sequences from the eastern
North Dakota isolates were translated (ExPASy; web.expasy.org/translate/)
and aligned with the previously typed isolates in ClustalW2. A Percent
Identity Matrix (PIM) was obtained. An OspC type group was assigned to
each eastern North Dakota isolate if the sequence did not diverge more than
2% from a particular group (99).
Multilocus Sequence Typing (MLST)
MLST was performed for each eastern North Dakota sample (198).
Primer sequences for the eight housekeeping genes used (clpA, clpX, nifS,
pepX, pyrG, recG, rplB, and uvrA) were obtained from the Imperial College
London’s B. burgdorferi MLST website (http://borrelia.mlst.net). For
amplification and sequencing, the outer forward and outer reverse primers
for each gene were used. For each gene, a 50 µL reaction was set up using
the HotStarTaq Plus Master Mix (QIAGEN) per the manufacturer’s
instructions. Primers were added to a final concentration of 1 µM and 1 µL of
purified genomic DNA was added. Previously described amplification
conditions were used (198) with the following modifications: 1. The initial
denaturing step was decreased to 5 min per the HotStarTaq Plus Master Mix
instructions and 2. The annealing temperature for recG was decreased to
48°C. Sequencing was performed at Eton BioSciences, Inc (San Diego, CA).
Chromatograms were inspected for double-peaks, which indicated a mixed
population. Chromatograms indicating mixed populations were omitted from
further analyses. Single locus queries were performed for each sequence to
obtain an allele number. An allelic profile query was performed with the
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available loci for each eastern North Dakota sample using the B. burgdorferi
MLST website. When data for eight loci were available, the query type chosen
was “Exact or nearest match.” When less loci were available, the query type
chosen was n-1, where n = number of available loci.
Infectivity of B. burgdorferi M3
Six female 4-6 week old BALB/c mice were each subcutaneously
injected with 106 spirochetes/mL. Two weeks post-injection, infection was
preliminarily determined by assaying pre- and post-infection sera by
enzyme-linked immunosorbent assay (ELISA). Larval I. scapularis were
allowed to feed on infected mice as previously described (203). Briefly,
approximately 200-300 uninfected larval I. scapularis (Oklahoma State
University-Stillwater) were placed on infected BALB/c mice, allowed to
attach, and feed. Four to seven days after attachment, engorged larval I.
scapularis dropped off, were collected, and placed in a humidified chamber
until they molted to nymphs. Mice were euthanized twenty-four hours after
all I. scapularis detached (i.e., day 8). One tibiotarsal joint, ear pinnae, and
the heart were collected for qPCR analysis. The second tibiotarsal joint and
ear pinnae were cultured in BSK-II medium with 6% rabbit serum and 50
µg/mL rifampin, blind passed, and examined by dark field microscopy as
described above. After molting, approximately 15 infected nymphal I.
scapularis were placed on 6 naïve female 4-6 week old BALB/c mice.
Engorged I. scapularis, mouse tissues, and cultures were treated as
described above.
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Enzyme-Linked Immunosorbent Assay (ELISA)
Anti-B. burgdorferi IgG in sera from inoculated mice was detected as
previously described (203). Briefly, 96-well plates were coated with a 10
µg/mL B. burgdorferi lysate in a carbonate coating buffer and incubated O/N
at 4°C. All washes were performed with PBS-Tween. Serum samples were
diluted 1:100 in PBS. Anti-mouse IgG was diluted 1:5000 in PBS. Each serum
sample was analyzed in triplicate.
DNA Extraction
DNA from bacterial cultures was extracted with a 25:24:1 phenolchloroform-isoamyl alcohol extraction. DNA was further purified with two
consecutive ethanol precipitations. Total (mouse and spirochete) DNA for use
in qPCR was extracted from tibiotarsal joints using a phenol-chloroformisoamyl alcohol protocol and further purified with the QIAGEN DNeasy Blood
and Tissue Kit per manufacturer’s specifications. Total DNA from hearts and
ear pinnae was extracted using a modified DNeasy Blood and Tissue Kit
protocol. Briefly, minced tissues were suspended in Buffer ATL with
proteinase K and incubated O/N at 56°C. Samples were further purified per
manufacturer’s specifications and as previously described (203).
Quantitative PCR (qPCR)
Primers used are listed in Table 2.1. Reactions were performed using
Bio-Rad iQ SYBR Green Supermix (Hercules, California). Mouse DNA was
detected using primers for nidogen (nid1) and quantified against 500, 50, 5,
0.5, 0.05, and 0.005 ng mouse DNA standards. Amplification conditions:
95°C for 3 min, 40 cycles of 95°C for 30, 49°C for 1 min, 1 cycle of 95°C for
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1 min, 50°C for 1 min, 1 cycle 49°C for 1 min, 49-95°C Δ0.5°C for 10 sec
each step. B. burgdorferi DNA was detected using primers for recA and
quantified against six B. burgdorferi DNA standards ranging in concentration
from 10-6 to 10-1 copy number. Amplification conditions: 95°C for 3 min, 40
cycles of 95°C for 30 sec, 50°C for 1 min, 1 cycle of 95°C for 1 min, 50°C for
1 min, 1 cycle 50°C for 1 min, 50-95°C Δ0.5°C for 10 sec each step. Each
sample and a no-template control were run in triplicate.
Detection of B. burgdorferi DNA in Nymphal I. scapularis
Total DNA was extracted from I. scapularis allowed to molt to nymphs
after feeding as larvae using a modified QIAGEN DNeasy Blood and Tissue Kit
protocol. Ten molted I. scapularis per mouse were homogenized in Buffer
ATL (600 µL) with proteinase K (20 µL) and incubated overnight at 56°C.
Buffer AL was added (200 µL); tubes were vortexed and incubated at 70°C
for 10 min. Wheat germ transfer RNA, Type V (1 µL of 10 mg/mL; R-7876,
Sigma-Aldrich; St. Louis, Missouri) was added and tubes vortexed. Ethanol
(230 µL, 95%) was added, tubes were vortexed, transferred to DNeasy spin
columns, and centrifuged for 1 min at 8000 rpm. Buffer AW1 (500 µL) was
added and centrifuged for 1 min at 8000 rom. Buffer AW2 (500 µL) was then
added and centrifuged at 14000 rpm for 3 min. DNA was eluted from the spin
column with 100 µL nuclease-free water twice. PCR was performed using
primers for I. scapularis 16S, B. burgdorferi 16S, and B. burgdorferi flaB
(Table 2.1) with the following amplification conditions: initial denaturation at
94°C for 3 min; 40 cycles of 94°C for 30 sec, 50°C for 30 sec, 65°C for 30
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sec; final elongation at 65°C for 5 min. Reactions were run on a 2.5%
NuSieve gel.
GenBank Accession Numbers
Sequences obtained in this study have been deposited with accession
numbers KM676013-KM676070.
Results
Sequence and Phylogeny Confirm Spirochetes are
B. burgdorferi and Represent Non-Clonal Populations
To confirm the eastern North Dakota samples were B. burgdorferi s.l.,
we sequenced 136 and 139 nucleotides of the 16S rDNA and flaB,
respectively. The 16S rDNA sequences were queried against the Ribosomal
Database Project. The sequences for each of the five samples returned hits to
various Borrelia species (data not shown). A BLAST search of the flaB
sequences obtained from all five samples showed 100% sequence identity
matches to B. burgdorferi (data not shown). These data confirmed the
spirochetes were members of the B. burgdorferi s.l. group.
To determine whether the samples represented multiple B. burgdorferi
populations or a single population, sequencing and phylogenetic analyses
were performed for ospA, ospC, p66, and the 16S-ile tRNA IGS. For
comparison, various B. burgdorferi s.l. and B. hermsii sequences were
obtained from the NCBI and BLAST databases. A BLAST search using the
16S-ile tRNA DNA sequence from B. burgdorferi B31 returned results for B.
burgdorferi s.l. (data not shown). There were no differences in the sequences
of ospA and p66 for the five samples. Protein maximum likelihood analyses of
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OspA (Fig. 2.1) and p66 (Fig. 2.2) grouped the eastern North Dakota
samples with B. burgdorferi s.l.

Figure 2. 1.

Unrooted protein maximum likelihood analysis of OspA shows
the eastern North Dakota isolates group with North American
B. burgdorferi. Sequences included, approximately, residues
41-236. Node values represent bootstrap values from 1000
replicates. Red: eastern North Dakota isolates; purple: North
America Lyme disease-associated Borrelia; blue: Eurasia
Lyme disease-associated Borrelia; black: unknown species.
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Figure 2. 2.

Rooted protein maximum likelihood analysis of p66 shows the
eastern North Dakota isolates group with North American
B. burgdorferi. Sequences included, approximately, residues
364-548. Node values represent bootstrap values from 1000
replicates. Red: eastern North Dakota isolates; purple: North
America Lyme disease-associated Borrelia; blue: Eurasia
Lyme disease-associated Borrelia; black: unknown species;
pink: Relapsing fever outgroup.
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Unlike OspA and p66, OspC showed variation among the eastern North
Dakota samples, sharing between 66 and 100% identity (Figs. 2.3 and 2.4).
In two of the small mammals sampled (M7 and M9), multiple B. burgdorferi
strains were detected. With the exception of B. burgdorferi M7 Clone 7, which
grouped with a clade consisting of both North American and Eurasian
Borrelia, the eastern North Dakota populations grouped most closely with B.
burgdorferi s.l. (Fig. 2.4). B. burgdorferi M9 Clones 1 and 6 were 100%
identical across the region used for OspC analyses, but showed variation
outside of this region, particularly at four residues immediately downstream.
Further sequencing would be required to determine whether Clones 1 and 6
are indeed different strains. OspC typing revealed a diverse group of
spirochetes (Table 2.2). Interestingly, one of the isolates identified, B.
burgdorferi M7 Clone 8, belongs to one of the rarer groups (L) to be
identified in reservoir animals (204). One isolate, B. burgdorferi M7 Clone 7,
did not group with OspC groups A-U. This is not surprising given it did not
clearly group with North American B. burgdorferi s.l. Taken together, these
data confirm non-clonal, invasive populations of B. burgdorferi are present in
eastern North Dakota.
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Figure 2. 3.

Alignment of OspC suggests the eastern North Dakota
isolates are genetically distinct strains of B. burgdorferi.
Samples M7 and M9 contain a mixture of clones. Sequences
included, approximately, residues 25-198. B. burgdorferi B31
(AE000792.1), N40 (DQ437463.1), B. burgdorferi A (a nontype strain, ABQ42987.1), B (a non-type strain,
ABK41066.1), ZS7 (AF500204.1), and JD1 (DQ437462.1), as
well as Vsp3, an OspC ortholog found in B. hermsii (relapsing
fever, AAA22967.1) were included for comparisons.
Alignment was performed in ClustalW2 and shading was
performed using ExPASy’s BoxShade.
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Figure 2. 4.

Rooted protein maximum likelihood analysis of OspC shows
the eastern North Dakota isolates group with North American
B. burgdorferi. OspC groups are indicated by a vertical black
line and single letter code. Sequences included,
approximately, residues 25-198. Node values represent
bootstrap values from 1000 replicates Red: eastern North
Dakota isolates; purple: North America Lyme diseaseassociated Borrelia; blue: Eurasia Lyme disease-associated
Borrelia; black: unknown species; pink: Relapsing fever
outgroup.
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Table 2. 2.

OspC group for each eastern North Dakota isolate using Wang et al.
(99) and Seinost et al. (98) groupings.

Eastern ND Isolate
B. burgdorferi M9 Clones 1 and 6
B. burgdorferi M3
B. burgdorferi M6
B. burgdorferi M4 and B. burgdorferi M9 Clone 2
B. burgdorferi M7 Clone 5
B. burgdorferi M7 Clone 8
B. burgdorferi M7 Clone 7

OspC group
A
B
E
F
I
L
None

The Eastern North Dakota Populations are Most Closely Related
to B. burgdorferi Found in the Upper Midwest
MLST analysis was performed to determine the regional source of the
eastern North Dakota populations. Loci were omitted from further analysis if
the chromatograms suggested a mixed population for that locus (i.e., double
peak at a single nucleotide location) (Tables 2.3 and 2.4). Sequence for all
eight loci could be obtained only for one sample (B. burgdorferi M9), thus
single locus analyses were performed for the remaining samples. The
database profiles that most closely matched the incomplete eastern North
Dakota sample profiles were obtained (Tables 2.3 and 2.4). B. burgdorferi M3
most closely matched ST30 strains for all loci except nifS, which was
unavailable. The available loci information for B. burgdorferi M4 matched
ST56 strains. B. burgdorferi M6 matched at five loci to ST31 and ST229 but
had a different recG loci than ST31 or ST229. B. burgdorferi M7 differed at
clpA from ST225 strains. B. burgdorferi M9 matched at all eight loci to ST56
strains. Each database strain that was the closest match to the eastern North
Dakota samples was initially identified in the Upper Midwest (Illinois,
Wisconsin, Minnesota, and Manitoba, Canada) (Fig. 2.5, Table 2.4). These
data suggest the eastern North Dakota samples are most closely related to
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Upper Midwest strains and thus, the Upper Midwest is the most probable
source of the eastern North Dakota samples.
Table 2. 3.

Allele scores for clpA, clpX, nifS, pepX, pyrG, recG, rplB, and
uvrA and closest matching database STs.

Eastern ND
clpA
clpX
nifS
pepX
Isolate
B. burgdorferi
19
1
-a
1
M3
B. burgdorferi
24
18
M4
B. burgdorferi
20
4
3
M6
B. burgdorferi
18
2
M7
B. burgdorferi
24
14
4
18
M9
a
Chromatogram indicated a mixed population
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pyrG

recG

rplB

uvrA

ST

2

1

1

10

30

-

19

1

-

3

1

3

-

2

8

1

-

56,
231
31,
229
225

11

19

1

12

56,
231

Table 2. 4.

Allelic profiles and sequence types (ST) for the eastern North Dakota
samples and the most closely matching multilocus sequence typing
database strains. Alleles that differ from the respective eastern
North Dakota allele are highlighted.
Sample/Strain
ST
clpA
clpX
nifS
pepX pyrG recG
rplB
uvrA
B. burgdorferi
M3
51405b
MC132
MC108

30
30
30

19
19
19
19

1
1
1
1

-a
5
5
5

1
1
1
1

2
2
2
2

1
1
1
1

1
1
1
1

10
10
10
10

B. burgdorferi
M4
1469205
MC73
MC78
Mid761
MC150

56
56
56
56
231

24
24
24
24
24
24

14
14
14
14
14

4
4
4
4
4

18
18
18
18
18
18

11
11
11
11
11

19
19
19
19
19
90

1
1
1
1
1
1

12
12
12
12
12

B. burgdorferi
M6
48102
50302
Mid471
MC101
MC92

31
31
31
229
229

20
20
20
20
20
20

4
4
4
4
4
4

3
3
3
3
3

3
3
3
3
3
3

3
3
3
3
3
3

1
3
3
3
18
18

3
3
3
3
3
3

3
3
3
3
3

B. burgdorferi
M7
MC110
MC120
BP-2

225
225
225

18
8
8
8

2
2
2
2

5
5
5

93
93
93

2
2
2
2

8
8
8
8

1
1
1
1

84
84
84

18
18
18
18
18
18

11
11
11
11
11
11

19
19
19
19
19
90

1
1
1
1
1
1

12
12
12
12
12
12

B. burgdorferi
M9
24
14
4
1469205
56
24
14
4
MC73
56
24
14
4
MC78
56
24
14
4
Mid761
56
24
14
4
MC150
231
24
14
4
a
Chromatogram indicated a mixed population
b
Database strain identifications
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Figure 2. 5.

Location of database STs from Table 2.4. Strains from
Marshfield Clinic, WI were obtained from unknown locations
in Wisconsin. All were identified from human erythema
migran samples. The remaining strains were reported to be
isolated from the identified location. Pink icons are ST225,
yellow ST31, orange ST30, green ST229 and ST231, cyan
ST56. Numbers in parentheses indicate the number of unique
strains comprising each ST. Forest River and Turtle River
were sites of sample collection in this study. Satellite images
obtained from NOAA via Google Earth.
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Needle-Injected B. burgdorferi M3 Infects and Survives in
BALB/c Mice and is Acquired by Larval I. scapularis During Feeding
To determine whether infectious and transmissible populations were
present in eastern North Dakota, an infection and transmission study was
performed using B. burgdorferi M3. M3 was the only sample obtained from
M. gapperi, whose reservoir status is unknown. Further, the OspC data
suggested M3 was a clonal population belonging to the infectious B group. An
ELISA of pre- and post-infection sera from mice subcutaneously injected with
106 B. burgdorferi M3/mL showed increased anti-Borrelia antibodies 2-weeks
post-injection (Table 2.5). Tibiotarsal joints and ear pinnae were culturepositive, except for one mouse where culture data were unavailable due to
contamination. B. burgdorferi flaB was detected in molted nymphs fed on five
of the six needle-injected mice (Table 2.5). Neither B. burgdorferi 16S nor
flaB could be positively identified in molted nymphs fed on mouse 6. B.
burgdorferi recA was detected in one of three hearts, six of six tibiotarsal
joints, and three of six ear pinnae (Table 2.6). The mouse nidogen gene,
nid1, was detected in all tissues (Table 2.6). These data demonstrate B.
burgdorferi M3 is infectious to mice, able to disseminate to multiple tissues,
and capable of being acquired by I. scapularis during a blood meal.
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Table 2. 5.

Summary of ELISA and culture results from mice either needleinjected (N) with 106 cells/mL B. burgdorferi M3 or tick-infected (T),
as well as PCR detection of B. burgdorferi flaB from nymphs reported
as B. burgdorferi flaB positive/nymph 16S positive.
ELISA
Culture
PCR
Needle-injected
Tick-infected
Tibiotarsal joint
Ear pinnae
Bb/Nymph
(N)
(T)
s
N
T
N
T
6/6
6/6
5/6a
6/6
6/6
6/6
5b/6
a
One culture contaminated after initial inoculation
b
PCR with B. burgdorferi 16S and fla were not clearly positive or negative for one
mouse

Table 2. 6.

Summary of qPCR for needle-injected and tick-infected mice
reported as B. burgdorferi recA positive/mouse nid1 positive.
Needle-injected
Tick-infected
Heart
Tibiotarsal
Ear pinnae
Heart
Tibiotarsal
Ear pinnae
joint
joint
1/3a
6/6
3/6
6/6
6/6
6/6
a
Neither recA nor nid1 were detectable in three mice

B. burgdorferi M3 Survives the I. scapularis Larval Molt
and is Subsequently Transmitted to Naïve BALB/c mice
During a Blood Meal
To determine whether B. burgdorferi M3 was transtadially maintained
during the I. scapularis larval molt and capable of transmission to naïve
mice, I. scapularis nymphs were fed on naïve BALB/c mice. Infection was
confirmed by ELISA, which showed an increase in absorbance post-feeding
(Table 2.5). Tibiotarsal joints and ear pinnae were all culture-positive. nid1
and recA were detected in all six hearts, tibiotarsal joints, and ear pinnae.
These data show B. burgdorferi M3 is transtadially maintained in I. scapularis
and capable of dissemination in naïve hosts.
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Discussion
Studies on the prevalence and spread of B. burgdorferi, I. scapularis,
and Lyme disease in the Upper Midwest typically focus on Minnesota and
Wisconsin (183, 205, 206). The vast majority of Lyme disease cases, and
thus B. burgdorferi and I. scapularis, reported in the Upper Midwest are
found in Minnesota and Wisconsin. However, there are numerous factors that
demanded a detailed investigation of B. burgdorferi in eastern North Dakota
(e.g., the close proximity to high-risk Minnesota counties with a history of
Lyme disease, B. burgdorferi, and I. scapularis; the presence of known small
mammal reservoirs; and recent studies (37, 180) identifying stable I.
scapularis populations and B. burgdorferi in North Dakota further confirming
the expansion of I. scapularis described in other US regions and Canada (41,
179, 181, 182, 207)]).
The data presented here demonstrate the spirochetes isolated in
eastern North Dakota from Peromyscus spp. and M. gapperi hearts are
members of the B. burgdorferi s.l. complex. While OspA and p66 are identical
among all of the eastern North Dakota populations, OspC typing shows they
are distinctly non-clonal populations. The M9 population consisted of at least
two OspC types, A and F; M7 consisted of at least two types, I and L (Table
2.2, Fig. 2.4). B. burgdorferi M7 Clone 7 does not appear to belong to any of
the previously defined OspC groups. In phylogenetic analyses, Clone 7 also
does not appear to group clearly with either North American B. burgdorferi
s.l. or Eurasian Lyme disease Borrelia (Fig. 2.4). A BLAST analysis with the
sequence from Clone 7 returns results for B. burgdorferi s.l. OspC but with a
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maximum identity score of 87% (data not shown). It is clear Clone 7 is a
member of the B. burgdorferi s.l. complex, but its OspC type and infectivity
remain unknown. Despite obtaining sequence data for a single clone, the M6
population may consist of multiple OspC types due to difficulties obtaining
ospC sequence prior to cloning ospC. Since less than five ospC clones were
obtained and sequenced from three of the five eastern North Dakota
samples, it is not possible to determine the proportion of OspC types in each
sample. It is clear at least three of the most common OspC types known to
cause disseminated infection in humans (A, B, and I) (98, 99) are present in
eastern North Dakota (Table 2.2, Fig. 2.4). A more comprehensive survey is
required to determine the presence and distribution of OspC types.
The MLST data, though limited, suggest the eastern North Dakota
populations are derived from the Upper Midwest populations and not a recent
transplant from another region. Specifically, the eastern North Dakota
populations appear to be most closely related to strains found in Minnesota,
Wisconsin, Illinois, and southeastern Manitoba on the Minnesota-Canada
border. A number of the housekeeping genes appeared to be identical in the
populations that the OspC data showed were mixed populations. Likewise, a
number of housekeeping genes appeared to indicate mixed populations in a
single sample when the OspC data suggested populations in each sample
were clonal. This was surprising because the ospC gene is highly
polymorphic, while the housekeeping genes are generally more conserved.
Viewing the OspC and MLST data together suggest that in addition to smallscale random mutation events, large-scale mutation events also occurred
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with OspC. The sequence analyses, taken as a whole, suggest a regional
population structure larger and more complex than was captured by the five
samples partially characterized here.
The results of the infection study show B. burgdorferi M3 is infectious
through both an artificial and natural route of infection. B. burgdorferi M3 is
capable of disseminating from the site of inoculation to the heart, tibiotarsal
joint, and ear pinnae indicating it is highly infectious (101). The ability to
disseminate is not surprising since B. burgdorferi M3 belongs to the ospC
group B, a group associated with disseminated disease in humans (98, 152,
193).
In the US, Lyme disease remains a significant public health issue.
From 2001 to 2011, the number of confirmed cases reported to the CDC
averaged 24,000 making it the most reported tick-borne disease in the US
(CDC). In 2013, the CDC released revised yearly estimates based on
continuing studies including analyzing data from tests conducted by seven
participating commercial laboratories in 2008 (78). Based on these analyses,
the estimated number of individuals infected with B. burgdorferi in the US
was revised to approximately 288,000 per year, about ten times more than
the average yearly number of reported and confirmed Lyme disease cases.
North Dakota is not the Lyme disease hotspot Minnesota is, but Lyme disease
is poised to be a significant public health issue in North Dakota. The number
of Lyme disease cases reported yearly in North Dakota is low (205 reported
cases between 1996 and 2015, North Dakota Department of Health),
compared to the number of cases reported in neighboring Minnesota (16,439
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confirmed cases between 1996 and 2015, Minnesota Department of Health).
However, just as the national cases are underestimated, there are a number
of factors that make a reasonable argument for cases in North Dakota being
underestimated: the classification of eastern North Dakota as a transition
zone (179), the conventional opinion that B. burgdorferi and I. scapularis are
not found in North Dakota, the evolving criteria for reporting and confirming
Lyme disease, the increasing number of Lyme disease cases in North Dakota,
and the rural nature of North Dakota.
To develop comprehensive, informed public health policies in both the
US and Canada, it is imperative to understand whether I. scapularis, and
subsequently B. burgdorferi, are expanding outside of the previously
identified geographical regions. While changes in habitat, and the reasons for
those changes, are outside the scope of this study, it is clear that B.
burgdorferi and I. scapularis have migrated westward in the Upper Midwest.
This information is relevant to North Dakota residents, visitors, and medical
professionals who should be aware of the risk of contracting Lyme disease in
eastern North Dakota. This information is also important beyond the borders
of North Dakota as it provides additional data on the ever-evolving state of
Lyme disease.
Acknowledgements
The authors would like to acknowledge Drs. Brian Stevenson, Brandon
Jutras, Jean Tsao, Patty Rosa, and Paul Mead for helpful discussions and
suggestions, and Megan Quinlan for obtaining a high-resolution map.

60

CHAPTER 3
IN VITRO AND IN VIVO CHARACTERIZATION OF TWO ANKYRIN
PROTEINS, BB0399 AND BBB28,
IN BORRELIA BURGDORFERI
Introduction
Lyme disease, an infection with Borrelia burgdorferi spread through
the bite of an infected Ixodes scapularis, is the leading tick-borne disease in
the US (4, 77). Each year 20,000-30,000 cases are reported to the CDC, but
new estimates increase the suspected cases ten-fold to 240,000-444,000 per
year (78). Despite the high incidence of Lyme disease, we still do not fully
understand mechanisms B. burgdorferi utilize to cause disease and survive in
reservoirs and vectors (208–210). One potential mechanism involves
ankyrin-repeat (Ank) proteins, which have recently been identified in
prokaryotes with several identified as virulence factors (211–251). Ank
domains commonly facilitate protein-protein interactions in eukaryotes. In
bacteria, three general functional classes of Ank proteins have been
identified: 1. DNA-binding (252), 2. Oxidative stress response (248), and 3.
Mimicking host Ank proteins (216, 238, 253, 254).
Based on BLAST searches and previous studies, our hypothesis was
bb0399 belonged to the first functional class and bbb28 belonged to the
second functional class.
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Ankyrin Proteins
The ankyrin-repeat domain (Ank) is one of the most common protein
motifs and has been identified in the genomes of bacteria, archaea,
eukaryotes, and viruses. The general structure of an ankyrin-repeat domain
consists of a 33-residue repeat forming a series of alpha helices that stack
upon each other forming a spring-like structure. A single domain can possess
between 2 and 34 repeats, with prokaryotic Ank proteins having an average
of four to six repeats for free-living/facultative host-associated and obligate
intracellular bacteria, respectively (242).
Eukaryotic Ank proteins exclusively mediate protein-protein
interactions (212) in diverse cellular processes, e.g. cell cycle regulation,
with functions such as transcription factors (246), toxins (widow spider
neurotoxins, (255)), and nucleases (RNase L, (256)). While less is known
regarding the role of bacterial Ank proteins, a handful have been
characterized to some degree and it is increasingly clear that Ank domains
are important virulence factors and play important roles in the survival of
bacteria (211, 216, 218, 238, 240, 248, 249, 252–254, 257, 258). One
theme that has emerged is the role of Ank proteins in mediating some aspect
of oxidative stress, with the two best characterized examples being AnkA
from Anaplasma phagocytophilum and AnkB from Pseudomonas aeruginosa.
AnkA
DNA-binding Ank proteins have been identified in Anaplasma (259)
and Ehrlichia (244). One of the better characterized is AnkA, a secreted,
soluble protein from A. phagocytophilum, a Gram-negative, obligate
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intracellular pathogen living in neutrophils. Once inside a neutrophil, A.
phagocytophilum secrets AnkA via a type IV secretion system. AnkA
translocates to the host nucleus where it: 1. Binds the host phosphatase,
SHP-1, to interfere with host cell signaling (223, 257) and 2. Directly binds
host DNA, specifically the cytochrome b-245 beta chain gene (CYBB)
promoter, to decrease CYBB transcription (211, 252). Cytochrome b-245 is
part of the oxidase system in phagocytic cells and is involved in the
formation of superoxide radicals.
AnkB
Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen.
AnkB is an integral cytoplasmic membrane protein, with the Ank domain on
the periplasmic side (248). ankB is cotranscribed in a small operon with katB,
a catalase only induced in response to H2O2 (248, 260). Deletion of ankB
decreases transcription of katB and makes cells more sensitive to H2O2
(248). While the mechanism or function of AnkB is unknown, two hypotheses
were proposed (248): 1. AnkB binds to and stabilizes or anchors KatB
allowing KatB to take an optimal conformation to bind and degrade H2O2, or
2. AnkB provides structural support for the cytoplasmic membrane to
mitigate an increase in turgor pressure from oxygen accumulated during the
degradation of H2O2.
Oxidative Stress
Oxygen is toxic, even to obligate aerobic bacteria (261). An inevitable
byproduct of aerobic cellular metabolism, especially oxidative
phosphorylation, is the production of reactive oxygen species (ROS), such as
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superoxide (O2·–) and hydrogen peroxide (H2O2) (262). If not fully detoxified,
superoxide or intermediates can cause irreparable damage eventually leading
to cell death. Some microaerophilic bacteria, which require low
concentrations of atmospheric oxygen, will use oxidative phosphorylation as
a major or sole source of ATP production. As a result, microaerophiles can
have a full collection of ROS-neutralizing enzymes. Helicobacter pylori and
some Campylobacter species have a superoxide dismutase (SOD) and
catalase (263–267); these microaerophilic species are able to fully detoxify
ROS. B. burgdorferi has no catalase and only a single manganese-dependent
SOD identified (22, 268). In fact, B. burgdorferi has no apparent sources of
endogenous ROS, e.g. oxidative phosphorylation, except for a putative
flavoenzyme (bb0812) that might be a source of endogenous superoxide
radicals (22, 268).
Oxidative Stress and B. burgdorferi
Whereas all other known pathogens have mechanisms to obtain iron
from hosts (e.g. siderophores) and have myriad iron-dependent enzymes, B.
burgdorferi has no siderophores, iron-dependent enzymes, or iron transport
mechanisms (268). Coupled with an intracellular iron concentration of less
than 10 atoms (269), B. burgdorferi is a pathogen that does not require iron.
The outer membrane lipid profile of B. burgdorferi is also unique among
pathogens. In addition to lipoproteins commonly found in the outer
membrane of most bacteria, e.g. phosphatidylethanolamine and
phosphatidylglycerol, B. burgdorferi also incorporates a large percentage of
eukaryotic-derived cholesterol and cholesterol-glycolipids and thus, have
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more polyunsaturated fatty acids (36% of the total fatty acids when grown in
vitro) compared to other bacteria (270). Because B. burgdorferi obtains
membrane lipids from its environment, the lipid profile can be highly variable
and reflective of the environment (271, 272). Polyunsaturated fatty acids are
more susceptible to lipid peroxidation, a potentially lethal reaction whereby
ROS create lipid peroxyl radicals and can eventually decrease membrane
fluidity.
This unique physiology precludes B. burgdorferi from the obvious and
well-characterized bacterial targets of ROS. B. burgdorferi is not susceptible
to DNA damage resulting from exposure to ROS (270). Hydroxyl radicals
from the breakdown of H2O2 can lead to protein carbonylation. While
carbonylation can be catalyzed by any metal, there is no evidence that
protein carbonylation occurs in B. burgdorferi as a result of ROS. The main
targets for ROS damage are the polyunsaturated fatty acids found in B.
burgdorferi’s membranes (270).
With no apparent source of endogenous ROS, B. burgdorferi likely
encounters ROS from exogenous sources, I. scapularis, and mammalian
hosts. Much remains unexplained regarding dissolved oxygen concentrations
and ROS production in I. scapularis. The dissolved oxygen content in the
midgut and salivary glands of I. scapularis have not been determined and so
whether or to what extent B. burgdorferi encounters ROS in I. scapularis is
unknown (273). We do know I. scapularis releases a large number of
proteins during feeding to minimize host immune responses (107), including
proteins that aid B. burgdorferi in various ways, particularly with ROS. Two
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salivary proteins directly inhibit neutrophils from producing ROS (274) and
Salp25D, a salivary peroxidase directly protects B. burgdorferi from
mammalian host oxidative damage during host-to-vector transmission (275,
276).
B. burgdorferi will encounter rapidly evolving oxygen concentrations as
it disseminates throughout a host. In rats, there is a concentration gradient
of dissolved oxygen with a four-fold higher concentration in arterial blood
than skin (273, 277, 278). Based on this, one hypothesis is that B.
burgdorferi will encounter much lower concentrations of ROS in the host’s
dermal layer until it encounters neutrophils. In addition to the neutrophil’s
intracellular oxidative burst, which releases ROS within a phagolysosome to
kill pathogens, neutrophils can release ROS into the extracellular space (276,
279, 280). Oxygen and ROS concentrations will likely vary by host organ and
the extent of oxygenation in areas where B. burgdorferi reside, e.g.
connective tissue at the base of the heart, is unknown. Still, B. burgdorferi
will have to survive some exposure to oxygen and ROS.
Studies on the effects of oxidative stress, particularly from hydrogen
peroxide (H2O2) on B. burgdorferi have produced conflicting results with
some groups showing B. burgdorferi is resistant to H2O2 (281) and others
showing B. burgdorferi is susceptible (282, 283). Recently, Troxell et al.
(282) confirmed wild-type B. burgdorferi is resistant to oxidative stress and
demonstrated the discrepancies in previous studies may be due to the
presence of pyruvate in B. burgdorferi culture medium. Pyruvate is a potent
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scavenger of H2O2 and added in excess of physiological concentrations in B.
burgdorferi culture medium.
B. burgdorferi Ankyrin Proteins
B. burgdorferi possesses two genes encoding proteins with Ank
domains, bb0399 and bbb28. These genes are two of the 588 hypothetical
proteins in the B. burgdorferi genome. Both bb0399 and bbb28 are actively
transcribed (284), however, the function(s) of bb0399 and bbb28 remain
unknown.
B. burgdorferi bbb28
B. burgdorferi type strain B31 possesses a gene, bbb28, with a
putative Ank domain consisting of two Ank repeats (Fig. 3.1). bbb28 is
located on circular plasmid 26 (cp26), a plasmid essential for B. burgdorferi
survival (285), and is highly conserved among B. burgdorferi strains (89100% sequence identity). A few studies have identified bbb28 or BBB28 but
those that have suggest bbb28 is functional, transcribed, and translated.
Yang et al. (286) found BBB28 co-precipitated with the inner membrane
protein, La7. Caimano et al. (287) found bbb28 decreased by approximately
half when the response regulator, rrp1, was knocked out. Rrp1, part of the
Hk1/Rrp1 two-component system, is vital for B. burgdorferi survival in I.
scapularis (288–290). Ojaimi et al. (284) found bbb28 was one of 50 highly
transcribed genes and transcription was high independent of temperature
(35°C used to mimic a mammalian infection and 23°C used to mimic I.
scapularis colonization) in wild-type (wt) B. burgdorferi type strain B31.
Ojaimi et al. (291) also compared global transcription in a wild-type, virulent
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Figure 3. 1.

Predicted features of BB0399 and BBB28 using European
Molecular Biology Laboratory’s Simple Modular Architecture
Research Tool database (EMBL SMART). A. BB0399 has four
Ank repeats and four regions of low complexity (pink boxes at
aa 14-29 and aa 202-211; two regions are not shown at aa
106-114 and 184-197). B. BBB28 has two Ank repeats and
two predicted transmembrane domains. (EMBL SMART found
at http://smart.embl-heidelberg.de/)

B. burgdorferi B31 isolate (BL206) and a high-passage, attenuated isolate
(B356; lacks lp25, cp32-6, and cp32-8). bbb28 transcription was higher in
the B356 isolate. RNA-seq analysis also found bbb28 was transcribed in wildtype B. burgdorferi B31 grown under normal conditions (292).
Hyde et al (293) found bbb28 transcription was downregulated in a
mutant B31 strain, JS167, that was as resistant to oxidative stress as the
wild-type strain, MSK5 (294). This difference in phenotype between mutant
and wild-type was attributed to the activity of a single protein, the Borrelia
oxidative stress regulator (BosR). In wild-type B. burgdorferi, BosR activates
genes involved in an oxidative stress response, e.g. superoxide dismutase

68

(sodA) and neutrophil activating protein A (napA; homologous with
Escherichia coli’s Dps, an iron-dependent DNA-binding protein that functions
to protect DNA during starvation and oxidative stress). B. burgdorferi B31
strain CHP100 was found to be hyper-sensitive to tert-butyl hydroperoxide
(t-BHP, damages outer membrane). The hyper-sensitive phenotype was due
to a single point mutation in bosR resulting in an arginine to lysine
substitution (bosRR39K). BosRR39K does not bind the promoter of napA but
does bind the promoter and repress sodA. Inactivation of bosRR39K by
transposon mutagenesis resulted in strain JS167 and restoration of the wildtype phenotype, ROS resistant. Thus, the model proposed is that BosR
activates transcription of oxidative stress response genes, BosRR39K
represses transcription of those genes, and inactivation of bosRR39K
derepresses those genes. Thus, we can infer bbb28 is activated in a wild-type
strain, repressed by BosRR39K, and derepressed by the inactivation of
bosRR39K.
Finally, signature-tagged mutagenesis (STM) of B. burgdorferi was
able to produce bbb28::kanR mutants that were used to infect mice (105).
Culture and PCR of five tissues were utilized to screen tissues for B.
burgdorferi at two and four weeks post-infection. The overall trend was one
of defective dissemination and/or survival of bbb28::kanR mutants outside of
the inoculation site.
B. burgdorferi bb0399
Less is known about bb0399. Expression of BB0399 is different in midexponential phase compared to stationary phase. A RelA/SpoT homolog
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(RelBbu) involved in B. burgdorferi persistence in ticks upregulates bb0399
expression during stationary phase, however, the increase in expression is
small compared to other RelBbu-regulated genes (log2 fold change = 1.96)
(295). Another study, also found bb0399 transcription was also different
during stationary phase but found bb0399 was decreased in stationary phase
(log2 fold change = -1.3) (292)Expression in wild-type B. burgdorferi B31 is
minimal and unaffected by temperature (284). Expression of bb0399
becomes undetectable when rrp1 is knocked out (287). Unlike with BBB28,
there are no data suggesting bb0399 transcripts are translated. STM was
unable to produce a bb0399::kanR mutant suggesting bb0399 is an essential
gene (105).
Objective
The goal of this work was to identify the function(s) of bbb28 and
bb0399. Our initial hypothesis focused on a BBB28 belonging to the oxidative
stress class of ankyrin proteins. Our hypothesis stated BBB28 had a direct
role in an oxidative stress response with an additional, or perhaps related,
role in host dissemination. Our oxidative stress hypothesis shifted to BBB28
not having a direct role in an oxidative stress response, rather, being
regulated by BosR in response to unknown stimuli. Our hypothesis for
BB0399 was that BB0399 is an essential gene and may have DNA-binding
properties, similar to AnkA of A. phagocytophilum.
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Materials and Methods
Cloning
Full-length bb0399, full-length bbb28, and truncated bbb28 (nt 1871245, bbb28∆186 encoding protein BBB28∆62) were cloned into five vectors
(Table 3.1). After ligating the target gene into the vector backbone, E. coli
Top10 was transformed with each plasmid except pMAL-p5X and pMAL-c5X,
which were transformed into NEB Express Competent E. coli (New England
BioLabs, Inc). Cultures were grown overnight in LB with the appropriate
antibiotic for selection. Up to 50 colonies per transformation were screened
by PCR for the presence of the correct insert using universal T7 or M13
primers as appropriate. Plasmid was then extracted from up to five PCRpositive colonies using Qiagen’s Midi Plasmid Purification kit per the
manufacturer’s instructions. Plasmids were sent for sequencing to either
Davis Sequencing or Eton Bio. Both strands were sequenced using either
universal T7 or M13 primers, as appropriate. Each sequence file was visually
inspected for sequence quality. A consensus sequence was obtained by
aligning the coding and non-coding strand files. Consensus sequence for each
insert was aligned to the appropriate sequence from B. burgdorferi B31. A
cloned insert had to match 100% to B. burgdorferi B31 before proceeding to
the transformation of an expression strain.
To transform an expression strain of E. coli, 50 ng of purified plasmid
was added to 50 µL of chemically competent E. coli. Five expression strains
were used: BL21(DE3) (Novagen), Rosetta pLysS (Novagen), Tuner
(Novagen), Tuner pLysS (Novagen), NEB Express Competent E. coli.
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Table 3. 1.

bbb28

bb0399

Gene

Cloning vectors, primers, and E. coli strains used in this study.
Restriction sites in primers, if present, are underlined.
Plasmid
Cloning Primers
E. coli
Vector
Name
Strain(s) Used Backbone
pBLS2
F:
Top10
pCR2.1
CGTCTAAAATTAAACACTTT
(Thermo
ATTAAAGG
Fisher
R:
Scientific)
ATATCCAAGCATCTGATGG
G
pBLS4
F:
BL21(DE3)
pET200
CACCATGCTTTTACTRTTAT
Rosetta pLysS
(Thermo
TGCAAACAATAATG
Tuner
Fisher
R:
Tuner pLysS
Scientific)
GGCTATTTTACTAAAATTCG
NEB Express
pMAL-c5X
pBLS10 F: PO4atgaaaaaagaattcattatgctttt
(New England
actgttattgcaaaca
BioLabs, Inc)
R (SbfI):
GAGAGAGACCTGCAGGCTA
TTTTACTAAAATTCG
pBLS9
F: PO4NEB Express
pMAL-p5X
ATGAAAAAAGAATTCATTAT
(New England
GCTTTTACTGTTATTGCAAA
BioLabs, Inc)
CA
R (SbfI):
GAGAGAGACCTGCAGGCTA
TTTTACTAAAATTCG
pBLS15
F (BamHI):
Tuner
pGEX-6P-1
CTCTCTGGATCCATGAAAAA Tuner pLysS
(GE Healthcare
AGAATTCATTATGCTTTTAC
Life Sciences)
TG
R (SalI):
CTCTCTGTCGACCTATTTTA
CTAAAATTCGAACTATTTCT
TTGTT
pBLS1
F:
Top10
pCR2.1
TATAATTTAAAAATAAACTTT
AAAAGGATG
R:
GCAATGGAATTAATCATCAA
TTAGC
pBLS3
F:
BL21(DE3)
pET200
CACCATGAGTTATTATGTGC Rosetta pLysS
TAAGCAAAATATT
Tuner
R:
Tuner pLysS
GTTAAATACCGATTAAATAT
TTATAGATTTCACTAG
pBLS8
F: PO4NEB Express
pMAL-c5X
ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG
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pBLS7

pBLS14

pBLS6

bbb28∆186

pBLS12

pBLS11

pBLS13

R (SbfI):
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT
F: PO4ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG
R (SbfI):
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT
F (BamHI):
CTCTCTGGATCCatgagttatt
atgtgctaagcaaaatattt
R (SalI):
CTCTCTGTCGACTTAAATAC
CGATTAAATATTTATAGATT
TC
F:
CACCttcaccgaaaagcaattatt
agaagattttaatattttcgaa
R:
GTTAAATACCGATTAAATAT
TTATAGATTTCACTAG
F: PO4ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG
R (SbfI):
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT
F: PO4ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG
R (SbfI):
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT
F (BamHI):
CTCTCTGGATCCTTCACCGA
AAAGCAATTATTAGAAGAT
R (SalI):
CTCTCTGTCGACTTAAATAC
CGATTAAATATTTATAGATT
TC
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NEB Express

pMAL-p5X

Tuner
Tuner pLysS

pGEX-6P-1

BL21(DE3)
Rosetta pLysS
Tuner
Tuner pLysS

pET200

NEB Express

pMAL-c5X

NEB Express

pMAL-p5X

Tuner
Tuner pLysS

pGEX-6P-1

Expression of Recombinant BB0399 and BBB28
Several protocols were used to attempt expression of recombinant
BB0399 and BBB28.
For the traditional induction, one colony was inoculated into 50 mL
Super Broth (SB) + 100 µL 50 µg/mL kanamycin (Kan) and grown overnight
at 37°C. Five mL of the starter culture was subcultured into 500 mL SB + 2.5
mL Kan and grown with shaking until OD600 was 0.4-0.6. One-hundred µL
was removed from each flask, pelleted, and stored at -20°C (pre-induction
sample). Isopropyl ß-D-1 thiogalactopyranoside (IPTG) was added to each
flask to a final concentration of 0.5 mM. One-hundred µL of induced culture
was removed 1 and 4 hours post-induction. After 4 hours, the remaining
induced culture was pelleted (6000 x g, 10 min) and stored at -20°C.
The same protocol was used for cultures grown and induced at 30 and 20°C.
In addition, all three protocols were attempted with 0.1 and 1 mM IPTG.
Two auto-induction protocols were used. The first attempt at autoinduction was performed using the Dual Media Set (EB + OB) (Zymo
Research) at 37, 30, and 20°C. Protocol II, which is designed for induction of
toxic proteins and insoluble proteins, was used. For each temperature, a
freshly streaked colony was inoculated into 5 mL EB medium and grown at
the appropriate temperature for 8 hours (starter culture). Fifteen mL of prewarmed EB medium was added with 0.25 mM IPTG to the starter culture and
incubated for 16 hours.
The second attempt at auto-induction was performed using Studier’s
methods at 37, 30, and 20°C (296). Briefly, strains were cultured in ZYM74

5052 (rich, auto-induction medium), MDA-5052 (enriched, fully defined autoinducing medium), and MD-5052 (minimal, auto-inducing medium) at 37 and
20°C without or with 0.1 mM IPTG for 16 hours.
Drunken induction was also attempted using a protocol was obtained
from Dr. Suba Nookala. Briefly, an overnight culture was grown with the
appropriate antibiotic. The overnight culture was subcultured (1:100 dilution)
into fresh LB with the appropriate antibiotic to an OD600 of 1.4-1.8. Cultures
were chilled to 8-10°C in an ice-water bath. One mL of culture was removed,
pelleted, resuspended in SDS-PAGE sample buffer, and stored at -20°C. IPTG
was added to a final concentration of 100 µM and 2% (v/v) ethanol was
added. Cultures were induced overnight at 20°C. After induction, the culture
was pelleted and resuspended in binding buffer (5 mM imidazole, 0.5 mM
NaCl, 20 mM Tris-HCl, pH 8), 0.1% Triton X-100, 100 µL DNase (10000 U/mL
stock), 1 mg/mL lysozyme, 1 mM MgCl2, and 5 mM ß-mercaptoethanol.
Samples were homogenized by pipetting for 2-3 minutes. One mL of 50X
phenylmethane sulfonyl fluoride (PMSF) was added. The lysate was sonicated
on ice and centrifuged at 8000 rpm, 4o°C, 30 min. Supernatants were
removed (soluble protein fraction) and both supernatants and pellets were
saved and analyzed by SDS-PAGE.
All whole cell lysates (pre- and post-induction) and purified protein
fractions were analyzed via SDS-PAGE.
Growth Curves
pBLS4 (bb0399 in pET200) and pBLS3 (bbb28 in pET200) in Tuner,
Tuner pLysS, and Rosetta pLysS and pBLS9 (bb0399 in pMAL-p5X) and
75

pBLS7 (bbb28 in pMAL-p5X) in NEB Express were grown in LB, LB + 1%
glucose, LB + 1% glycerol, SB, ZYM-5052, MDA-5052, MD-5052, and MDG
(non-inducing medium) at 20 and 37°C for 140 and 68 hours, respectively,
using a Bioscreen C Analyzer (Growth Curves USA). Plates were shaken
continuously and OD600 was read every hour.
Purification of Recombinant Proteins
Soluble (pET200, pGEX-6P-1 constructs), insoluble (pET200, pGEX-6P1 constructs), inclusion body (pGEX-6P-1 constructs), cytoplasmic (pMAL-c5X
constructs), and periplasmic (pMAL-p5X constructs) fraction was extracted
when appropriate per manufacturer’s instructions.
Briefly, soluble and insoluble fractions from pET200 constructs were
isolated using B-PER II (Bacterial Protein Extraction Reagent; Pierce). Soluble
protein fractions were purified with the MagneHis Protein Purification System
(Promega) per manufacturer’s instructions. Protein fractions where
recombinant BB0339, BBB28, or BBB28Δ62 would have been were they
expressed in E. coli transformed with pMAL-c5X or pMAL-p5X were purified
using the New England BioLab’s cytoplasmic or periplasmic (osmotic shock)
isolation protocol, respectively. Inclusion bodies were purified Protein
fractions from E. coli transformed with pGEX-6P-1 were purified by
resuspending pellets in 1/20 volume PBS. Cells were sonicated on ice to lyse
(8 cycles at 40% amp, 20 sec on, 30 sec off). Triton x-100 was added to a
final concentration of 1% then incubated for 30 min at RT on an orbital
shaker. Samples were centrifuged 5 min, 4°C, 10000 x g. Supernatant was
removed and both supernatant and pellet were saved.
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Inclusion bodies were purified by one of two methods. The first
method used the MagneHis Protein Purification System protocol per
manufacturer’s instructions. The second method is as follows: 100 mL
cultures were pelleted and resuspended in 4 mL 20 mM Tris-HCl, pH 8. Cell
suspensions were sonicated on ice (4 cycles at 30% amp, 10 sec on, 20 sec
off) and centrifuged (20 min, 4°C, 15000 x g). Pellets were resuspended in
6 mL ice-cold purification buffer (2 M urea, 20 mM Tris-HCl, 0.5 M NaCl, 2%
Triton X-100), sonicated, and centrifuged until the supernatant was clear.
The pellet was resuspended in 5 mL solubilization buffer (20 mM Tris-HCl,
0.5 M NaCl, 5 mM imidazole, 6 M guanidine-HCl, 1 mM ß-mercaptoethanol,
pH 8) and incubated 60 min, RT, on an orbital shaker. Samples were
centrifuged 30 min, 4°C, 15000 x g. Prior to analyzing samples by SDSPAGE, proteins resuspended in guanidine were precipitated and resuspended
in urea using a modified protocol (297). Briefly, 200 µL of guanidine extract
was added to 1 mL of RT 95% ethanol, incubated overnight at -80°C, then
centrifuged at 14000 x g, 30 min, 4°C. Supernatant was removed and the
pellet was resuspended in 250 µL of -20°C 70% ethanol, vortexed, and
centrifuged 14000 x g, 10 min, RT. Supernatant and residual ethanol was
removed and the pellet was air dried for 15 min. Pellets were resuspended in
50-100 µL 8 M urea. Samples were then mixed with SDS-PAGE loading buffer
and incubated at RT for 30 minutes before loading on a gel.
Dot Blots
pGEX dot blots were performed using pBLS14 and pBLS15 in Rosetta
pLysS, BL21, Tuner, and Tuner pLysS induced at 20 and 37°C as described
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above for the traditional induction and Studier’s ZYM-5052 autoinduction
medium. After induction, soluble fraction was isolated as described above for
pGEX-6P-1 constructs. PVDF membranes were dipped in methanol until
transparent then equilibrated in 1X TBS without Tween-20 for 10 minutes.
Whatman filter paper was dipped in 1X TBS and placed on a clean weigh
boat. The PVDF membrane was placed on the filter paper and quickly dotted
with 1 and 2 µL of each supernatant. The membrane was removed from the
filter paper and allowed to dry completely. The dried membrane was wet in
methanol, briefly washed in 1X TBS, then blocked for 1 h at RT in 5%
blocking buffer (1X TBS-T + 5% non-fat dried milk). The membrane was
incubated with primary antibody (1:1000 mouse anti-GST, Pierce) for 2 h at
RT. The membrane was washed eight times with 1X TBS-T then incubated
with secondary antibody (1:10000 mouse anti-IgG, Pierce) for 1 h at RT. The
membrane was immediately developed with the Pierce SuperSignal West Pico
Chemiluminescent kit per manufacturer’s instructions.
Inclusion bodies were also analyzed via dot blot. The same protocol as
described above was used with pET200 constructs, 1:2500 rabbit anti-His
primary antibody (Thermo Fisher), and 1:10000 rabbit anti-IgG ECL
secondary (GE Healthcare).
Production of Polyclonal Anti-BBB28 Antibodies
Using the full-length BBB28 sequence, putative antigenic regions were
determined using EMBOSS explorer antigenic tool and the Universidad
Complutense Madrid antigenic peptide prediction tool (298). A 411 bp region
of the putative exposed region was cloned into a pET200/D-TOPO vector
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(Invitrogen) and expressed in Escherichia coli λDE3 BL21 Star (Invitrogen).
Recombinant protein was purified using the MagneHis Protein Purification
System (Promega) per manufacturer’s instructions and used to produce
polyclonal anti-BBB28 antibodies from 4- to 6-week-old C3H/HeN mice.
Purified protein was dialyzed into 1X PBS treated for animal injection. A preimmune cheek bleed was obtained for each mouse and analyzed via an
ELISA using whole-cell B. burgdorferi lysates and purified BBB28 peptide.
Purified peptide was suspended 1:1 in Alhydrogel adjuvant 2% (InvivoGen)
per manufacturer’s instructions. Each mouse received 50 µL of the peptide
and adjuvant mixture intraperitoneally on day 1, 14, and 28. On day 28,
blood was collected via submandibular bleed and analyzed via ELISA to
confirm production of antibodies against B. burgdorferi whole cell lysate. Mice
were then sacrificed, blood was collected, and serum was separated and
stored at -20°C.
Oxidative Stress
Determining Effects of Preparing Culture
for Oxidative Stress Exposure
B. burgdorferi 5A18NP1, an infectious isolate of the B31 type strain
(299), was cultured in BSK-II medium with 6% rabbit serum (complete BSKII) at 34°C + 5% CO2 to a cell density of 5 x 107 cells/mL. Cells were
centrifuged, washed, and resuspended in modified BSK-II (no rabbit serum
or sodium pyruvate) as previously described (282) with one modification.
Resuspended cultures were incubated at 34°C + 5% CO2 for 30 minutes in
modified BSK-II prior to ROS exposure. A 10 mL aliquot was removed
immediately prior to transfer, immediately after transfer, after a 30-minute
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incubation in modified BSK-II, and then 5, 10, 20, 30, and 60 minutes postincubation.
RNA was isolated using Trizol and isopropanol precipitation. cDNA was
synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen) and
used in quantitative PCR (qPCR). Transcripts for bosR and napA were
normalized to flaB and compared to expression at: 1. Pre-transfer
(+pyruvate) baseline, 2. Immediately post-transfer (-pyruvate, 0 min), or 3.
30 minutes post-transfer (-pyruvate, 30 min).
Oxidative Stress
B. burgdorferi 5A18NP1 was cultured in BSK-II with 6% rabbit serum
at 34°C + 5% CO2 to a density of 5 x 107 cells/mL. Cells were centrifuged,
washed, and resuspended as described above in modified BSK-II. After a
30 minute acclimation period, a 10 mL aliquot was removed (time 0). One
mM H2O2 or t-BHP were added to each culture. Ten mL aliquots were
removed 5, 10, 20, 30, and 60 minutes post-treatment. Cultures were
maintained in an ice-water bath until centrifuged. Pellets were washed three
times with 1X PBS and stored at -80°C until RNA extraction.
Quantitative Real-Time PCR
RNA was isolated using Trizol and isopropanol precipitation. cDNA was
synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen) and
used in quantitative PCR (qPCR). qPCR was performed for flaB, bosR, napA,
sodA, bb0399, and bbb28 (primers in Table 3.2) using SYBR Green Master
Mix (Bio-Rad) and the following protocol: 1 cycle at 95°C for 3 min, 40 cycles
at 95°C for 30 sec and 56°C for 1 min. Melt curves were 1 cycle at 95°C for 1
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min, 1 cycle at 56°C, 10 seconds at 56-95°C with 0.5°C temperature change
per cycle. Transcripts were normalized to flaB.
Table 3. 2.
qRT-PCR primers used in this study.
Amplicon target
Primer sequence
flaB
F: GGGTCTCAAGCGTCTTGG
R: GAACCGGTGCAGCCTGAG
bosR
F: AGCTTGGCTTCCACAATAGC
R: TTTGTTTCCCAGTTTTCTCCA
napA
F: GAAAGCATTGTTTGCAGTCT
R: AAAACAATCGCAATTTTCAA
sodA
F: AGAACTTTAAGGCCAGGAAA
R: CAATACTAACCATGCCCAAC
bb0399
F: TGCACTAAATCTTGGAGCAGAA
R: GCTCCGCTTTCTTTTAAAAATTC
bbb28
F: TTCCAACGGCAATCCAATA
R: GCGCCTTTTTCGATAAGTGA

Results and Discussion
In silico Analysis of BB0399 and BBB28
BB0399 is a small protein of 219 amino acids (Fig. 3.1A, Fig. 3.2A). It
has four predicted Ank repeats and four predicted regions of low complexity.
The presence of low complexity regions near the C- and N-termini suggest
BB0399 may be a promiscuous protein with numerous binding partners
(300). BBB28 is 414 amino acids with two predicted Ank repeats (residues
326-355 and 359-389) and two transmembrane domains residues 5-27 and
40-62) (Fig. 3.1B, Fig. 3.2B). Interestingly, the transmembrane domains
predicted for BBB28 in B. burgdorferi B31 are not predicted in B. bavariensis
PBi, a related Lyme disease Borrelia. In B. bavariensis PBi, the N-terminal
region is annotated as a low complexity region.
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Figure 3. 2.

Hydrophobicity plots by TopPred for BB0399 and BBB28.
A. Hydrophobicity plot for BB0399 predicts a soluble protein.
B. Plot predicts two transmembrane domains, indicated by
the two hydrophobic regions near the N-terminal.

Hydrophobicity plots (TopPred Version 1.10, (301)) suggest BB0399 is
a soluble protein with the Ank domain (residues 73-199) representing the
least hydrophilic region (Fig. 3.2A). TopPred also predicted two
transmembrane domains in BBB28 (Fig. 3.2B). Again, there is a sharp
increase in hydrophobicity within the Ank domain (residues 326-389)
compared to the rest of the protein (excluding the transmembrane domains).
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Protein BLAST (Blastp, NCBI) searches of BB0399 and BBB28 from B.
burgdorferi B31 produced no significant matches when Borrelia spp. were
excluded, except the conserved Ank domain structure. The Ank domain
aligned with a variety of organisms from bacteria (e.g. Wolbachia, Bacillus,
Lentisphaerae) to insects (e.g. Culex spp., Vollenhovia spp., Athalia spp.) to
trees and grasses (e.g. Prunus spp., Zea spp.) to mollusks (Mizuhopecten
spp.) (Fig. 3.3, 3.4; Tables 1 and 2 in Appendix).
Phyre2 is a tool that predicts protein structure through alignments and
domain homology to create 3D models (302). The most likely models for
BB0399 and BBB28 were produced using an intensive search (Fig. 3.5). For
BB0399, 97% of the residues were modeled at greater than 90% confidence
and for BBB28, 71% of the residues were modeled at greater than 90%
confidence.
Cloning and Recombinant Protein Expression
Numerous inductions for recombinant BB0399 and BBB28 failed
regardless of induction conditions or expression vector used. After one failed
induction, plasmid was extracted from cultures and sequenced. These results
revealed a stop codon resulting in premature termination of both proteins.
Since both bb0399 and bbb28 were sequenced prior to expression and no
stop codons were present, this suggests bb0399 and bbb28 are toxic to E.
coli and were mutated to prevent expression. The presence of an antibiotic
gene on each expression plasmid and culturing under selective pressure
prevented E. coli from removing the plasmid containing bb0399 or bbb28.
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Figure 3. 3.

Alignment for BB0399 adapted from NCBI protein BLAST
results.
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Figure 3. 4.

Alignment for BBB28 adapted from NCBI protein BLAST
results.
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Figure 3. 5.

Predicted structures of BB0399 (A) and BBB28 (B) by Phyre2.
Each structure is colored from the N-terminal (blue) to the
C-terminal (red). A. Ank repeats show the most secondary
structure (green to red helix-turn-helix motifs near the
C-terminal). B. Putative transmembrane domains are shown
in blue at the N-terminal. Ank repeats are in light green to
red.
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A handful of induction attempts produced promising SDS-PAGE, dot
blot, and Western results but were unable to be confirmed by additional
methods. For example, a dot blot for the glutathione S-transferase (GST) tag
found on recombinant protein expressed from pGEX vectors and 6X-Histidine
(His) tag found on recombinant protein expressed from pET vectors showed
some strains produced GST or His after induction but not before induction
(Fig. 3.6). The negative dots did have detectable protein when stained with
either Coomassie blue or Ponceau S. These results confirmed inducing
expression of recombinant BB0399 or BBB28 was possible with some strains.
An obvious drawback of dot blots is the inability to determine whether
antibodies are detecting the purification tag alone or tagged recombinant
protein. Western blots with the same samples were not positive, even for the
tag alone.
The goal for producing recombinant protein was to produce antibodies
against BB0399 and BBB28 for use in in vivo experiments. In a final attempt
to obtain antibodies to BB0399 and BBB28, a non-coding, highly antigenic
peptide was cloned into a pET200 TOPO vector (Invitrogen) (Fig. 3.7). The
peptides chosen covered several putative antigenic regions and at least part
of the peptide was expected to be available for antibody binding under native
folding conditions. There was a 50% success rate as only the bbb28 peptide
was successfully cloned and expressed. ELISA results from mice injected with
bbb28 peptide showed antibodies were produced that recognized whole B.
burgdorferi lysate.
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Figure 3. 6.

Dot blot for GST (pGEX) and His (pET) in soluble and
inclusion body fractions isolated from Tuner and Tuner pLysS
E. coli strains. Three E. coli strains transformed with pGEX
constructs (columns 1-3) had detectable GST in the soluble
fraction throughout the experiment, while the other three
strains (columns 4-6) showed detectable GST after induction.
Detection of His was weak throughout the experiment.
Column 1 – E. coli Tuner bb0399 in pGEX, 2 – Tuner pLysS
bb0399, 3 – Tuner bbb28, 4 – Tuner pLysS bbb28, 5 – Tuner
with truncated bbb28 (bbb28Δ186), 6 – Tuner pLysS
bbb28Δ186, 7 – Tuner bb0399 in pET200, 8 – Tuner pLysS
bb0399, 9 – Tuner bbb28, 10 – Tuner pLysS bbb28.
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Figure 3. 7.

Predicted antigenic peptides. (A) BB0399 peptides predicted
to antigenic are shown as horizontal grey bars at the top of
the plot. A region covering five putative antigenic peptides,
marked by yellow vertical lines, was cloned into a pET200
TOPO vector. (B) BBB28 peptides predicted to be antigenic. A
region covering seven putative antigenic peptides, marked by
yellow vertical lines, was cloned into a pET200 TOPO vector.
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Growth Curves
With evidence that both BB0399 and BBB28 are toxic to E. coli and
after several failed attempts to express recombinant protein, auto-induction
medium was used. Smaller yields of toxic proteins can be obtained under
certain conditions, such as inducing at lower temperatures or at higher cell
density. During auto-induction, starter cultures are grown in non-inducing
media containing a lac repressor, such as excess glucose. Cultures are then
subcultured into auto-inducing media, which also contains an appropriate lac
repressor as well as an additional carbon source. As the culture expands,
glucose depletes, cells begin using the second carbon source, such as
lactose, lac is no longer repressed, and recombinant protein is expressed.
Growth curves were performed to determine the best non-inducing medium,
auto-inducing medium, as well as the optimal length for induction.
All strains grew faster at 37°C (Fig. 3.9) compared to 20°C (Fig. 3.8).
MDG was found to be the best non-inducing medium. Strains grew well in all
auto-inducing media but for induction at 20°C, 16-24 hours was not enough
time for cultures to reach stationary phase. Cultures required at least 40
hours to reach stationary phase at 20°C. As a result, prior cultures were
harvested too early. Unfortunately, longer induction times in auto-inducing
media failed.
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Figure 3. 8.

Growth curves for E. coli transformed with one of eight
plasmids and cultured in eight types of media at 20°C. For all
strains, MDG medium was found to be the best non-inducing
medium. For auto-induction, all strains grew well in all autoinducing media but required much longer incubations than
recommended (30-40 hours to reach stationary phase
compared to the 16-24 hours recommended).
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Figure 3. 9.

Growth curves for E. coli transformed with one of eight
plasmids and cultured in eight types of media at 37°C. For
unknown reasons, no data points were recorded between 29
and 44 hours resulting in missing data points. In addition,
two strains (bb0399 and bbb28 Tuner) did not grow in LB or
SB. These wells were likely not inoculated with the starter
culture.
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Troubleshooting failed recombinant protein expression can be a
maddening experience as there are several factors (e.g. codon optimization,
properties of the chosen protein, vectors, expression strains, and induction
parameters) that can affect expression.
Codon Usage
Borrelia tends to use rare codons much more frequently. To
circumvent this problem, use of an E. coli strain capable of overproducing
tRNAs for these rare codons, such as a Rosetta pLysS E. coli strain is usually
recommended for routine expression of Borrelia proteins. Codon optimization
(replacing rare codons with common codons) is also performed and
recommended for genes encoded with several rare codons. Codon
optimization was not performed as neither BB0399 nor BBB28 possess a high
percentage of rare codons compared to other B. burgdorferi proteins.
Expressing recombinant BB0399 and BBB28 using any E. coli transformed
with pLysS was deemed sufficient.
Recombinant Protein Properties
Transmembrane domains can also impede recombinant protein
expression. Two approaches are available to express recombinant integral
proteins: 1. Clone the protein without the transmembrane domains or 2.
Express recombinant protein in an E. coli strain designed to express
membrane proteins, such as the OverExpress C41(DE3) or C43(DE3) E. coli
strains (Lucigen).

99

Vector and Expression E. coli Choice
If you adore customization, cloning is for you. Every piece of a vector
can be customized to fit your needs. The choice of purification tag can help
increase solubility of recombinant proteins, making them easier to purify.
There are also non-bacterial expression systems available, which could
eliminate several problems associated with expressing bacterial proteins.
Induction Parameters
If using an IPTG-inducible promoter, the presence of repressors in
culture medium, temperature before and during induction, duration of
induction, cell concentration at the time of induction, and IPTG concentration
used can all affect expression.
Oxidative Stress
Preparing Cultures for t-BHP Exposure
Affects Gene Transcription
Care must be taken when determining the effect of ROS on B.
burgdorferi. In addition to the unusual physiology (e.g. little intracellular
iron, no oxidative phosphorylation pathway), the medium used to culture B.
burgdorferi, BSK-II, possesses several components capable of scavenging
ROS. The one component found to be a potent scavenger of ROS is pyruvate,
which is added in physiological excess in BSK-II (282). Initially, H2O2 or tBHP were added immediately after transferring B. burgdorferi to pyruvatefree BSK-II. Results from these experiments and knowledge of bacterial
stress responses suggested B. burgdorferi was experiencing stress unrelated
to the presence of ROS. To test this hypothesis, expression of two control
genes, bosR and napA, was evaluated under three culture conditions.
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Expression of bosR and napA was found to significantly increase
immediately after transfer to pyruvate-free medium (-pyruvate, 0 min;
Fig. 3.10). A 30-minute incubation in pyruvate-free BSK-II returned
expression of bosR and napA to levels seen prior to resuspension (-pyruvate,
30 min; Fig. 3.10). Based on these results, cultures were washed and
resuspended in pyruvate-free BSK-II and incubated for 30 minutes prior to
the addition of either H2O2 or t-BHP.

Figure 3. 10.

Preparing B. burgdorferi for exposure to ROS appears to
affect the expression of bosR. A similar trend was observed
with napA.
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Transcription of bbb28, but not bb0399,
Appears to Increase in the Presence of t-BHP
To determine the expression of bb0399 and bbb28 in response to tBHP, B. burgdorferi was cultured in complete BSK-II, resuspended in
pyruvate-free BSK-II, incubated for 30 minutes then treated with 0 or 1 mM
t-BHP. Aliquots were removed immediately prior to ROS addition and then at
5, 10, 20, 30, and 60 minutes after addition of ROS. qRT-PCR data were
unavailable for some time points and genes. However, expression of bbb28
was highest 5 minutes after the addition of t-BHP and a time-dependent
decrease in transcription was observed (Fig. 3.11).
Whether the changes in bbb28 transcription observed after the
addition of t-BHP are due to the presence of ROS is still unknown.
Undoubtedly, centrifugation, resuspension, and placement into different
medium affect gene transcription in B. burgdorferi. To better elucidate the
effect of ROS on bbb28 transcription, a promoter fusion or reporter strain is
required. A reporter strain would allow direct observation of promoter
activation in response to ROS.
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Figure 3. 11.

Transcription of bbb28 increases after exposure to 1 mM
t-BHP. (A) Transcription of bosR, sodA, napA, bb0399, and
bbb28 in the absence of t-BHP. Transcription of bosR and
bb0399 increased, while bbb28 transcription decreased over
time in the absence of t-BHP. qRT-PCR failed for sodA at 30
and 60 minutes, napA at 10, 20, and 30 minutes, and bbb28
at 30 minutes. (B) Transcription in the presence of 1 mM tBHP. A strong increase in bbb28 transcription was observed 5
minutes after addition of 1 mM t-BHP. qRT-PCR failed for
sodA at 5 minutes and all transcripts at 60 minutes.
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Conclusions
This project provided ample learning opportunities to learn new
methods and troubleshoot methods. Unfortunately, I was unable to provide
additional information regarding the function of BB0399 or BBB28. Both
bb0399 and bbb28 are transcribed and others have shown at least BBB28 is
translated (286). The placement of bb0399 on the chromosome (22) as well
as the inability to knockout bb0399 (105) strongly suggests this is an
essential gene. Similarly, the placement of bbb28 on cp26, an essential
plasmid for B. burgdorferi, suggests the function of BBB28 is important,
though not essential for survival in vitro or in mice as mutants have been
recovered (105). In addition, understanding the function of bb0399 and
bbb28 would add to our understanding of B. burgdorferi, regardless of
whether this information would move from the realm of basic science into
translational research.
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CHAPTER 4
IN VITRO CHARACTERIZATION OF BORRELIA MIYAMOTOI
AND THE EFFECT OF AGE ON BORRELIA MIYAMOTOI INFECTION
IN WILD-TYPE C3H/HEN MICE
Introduction
Borrelia miyamotoi is a relapsing fever spirochete (20, 21, 85, 86,
175, 303–309) carried by the same Ixodes spp. that vector and carry species
of the Borrelia burgdorferi sensu lato (s.l.) complex in North America,
Europe, and Asia (20, 310). While first characterized in 1995 by Fukunaga et
al (20), B. miyamotoi was likely first reported in 1987 when Lane and
Burgdorfer (46) noted transovarial transmission of spirochetes in I. pacificus
and attributed the spirochetes as B. burgdorferi.
In general, Lyme disease Borrelia are associated with hard-shell ticks
and relapsing fever Borrelia are associated with soft-shell ticks. In addition to
B. miyamotoi, there are currently four documented exceptions. B. recurrentis
is a louse-borne relapsing fever spirochete presently endemic predominantly
to sub-Saharan Africa. B. theileri is the causative agent of bovine borreliosis
and is transmitted by Rhipicephalus microplus, a hard-shell tick that
parasitizes livestock (17). B. lonestari and B. turcica are genetically similar to
relapsing fever borreliae and carried by the hard-shell ticks Amblyomma
americanum and Hyalomma aegyptium, respectively (18, 19). The status of
B. lonestari and B. turcica as an animal or human pathogens is unknown.
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B. recurrentis and B. miyamotoi are the only relapsing fever Borrelia
transmitted by a vector other than Ornithodoros that are confirmed to cause
human disease (82, 87–93, 311). Despite the different vectors, pathology of
B. miyamotoi disease (BMD) or hard tick-borne relapsing fever (HTBRF)
appears to be similar to tick-borne relapsing fever (TBRF) with
immunocompetent patients reporting mild, recurrent but self-resolving febrile
episodes (Fig. 4.1) (87–93). Due to the generally mild nature of B.
miyamotoi infection, much of the attention given to B. miyamotoi has been
from researchers intrigued by this unusual pathogen.
There are several questions surrounding B. miyamotoi. So far, all of
these questions stem from our current knowledge of B. burgdorferi and the
relapsing fever Borrelia. Without an identified natural reservoir for B.
miyamotoi, we are limited in our ability to study the physiology of B.
miyamotoi as well as transmission and maintenance in Ixodes in the
laboratory. An initial hurdle to studying B. miyamotoi was the inability to
culture B. miyamotoi in vitro. Despite initial reports of growth in BarbourStoenner-Kelly-II (BSK-II) medium (20, 21, 175, 200), more recent attempts
to culture B. miyamotoi had been unsuccessful (310, 312). In 2014 and
2015, however, a major breakthrough was made when two in vitro culture
systems were developed (172, 313) and subsequently modified for use in our
laboratory (314). Additionally, to study transmission and maintenance in
Ixodes requires an adequate animal model. Immunocompromised mice are
able to maintain an infection (176, 315). However, an immunocompetent
mouse model would allow for more accurate investigations of the acquisition
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of B. miyamotoi by Ixodes as well as allow further study into the
immunological responses by hosts.

Figure 4. 1.

Depiction of the general course of tick-borne relapsing fever.
Approximately seven days after an infected tick bites, an
increase is observed in the concentration of spirochetes in
blood. Concomitant with a peak in spirochete concentration is
the onset of the first febrile episode. As spirochetes are
cleared from the blood, antigenic variation of variable
membrane proteins (VMPs) allows a second population of
spirochetes to expand. This leads to another, yet slightly less
severe, peak in spirochetemia and febrile episode. This cycle
of clearing and expansion occurs for an average of three to
ten times.
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An Overview of the Complement System
The complement system, composed of the classical, lectin, and
alternative branches, is a crucial component of the immune system
(Fig. 4.2). Components of complement continuously circulate in blood making
complement one of the first lines of defense against pathogens. Complement
initiates an immune response by: 1. Triggering phagocytosis through
opsonization, 2. Mediating inflammation through the release of chemotactic
peptides, and 3. Lysing cells via the membrane attack complex (MAC, also
called the terminal complement complex or TCC) (Fig. 4.2) (316).
The classical pathway is generally mediated by non-specific antibodies,
immunoglobulin G (IgG) or IgM, binding a bacterial antigen. Importantly,
recent studies have shown Borrelia-specific IgM is produced by a subset of B
cells during infection and play a crucial role in clearing Borrelia (125–127,
129–131, 317–319). The C1 complex, composed of C1q, C1r, and C1s,
forms upon recognition of bound IgG or IgM. C1 cleaves C2 (C2a, C2b) and
C4 (C4a, C4b). C4b covalently binds the target’s cell surface and complexes
with C2a to form C3 convertase, which cleaves C3 into C3a and C3b. C3b
covalently binds the target cell surface (opsonization, facilitates phagocytosis
of foreign cells and cellular debris), while C3a remains soluble to act as a
mediator of inflammation. C5 convertase forms when C3b binds C3
convertase. Not surprisingly, C5 convertase cleaves C5 into C5a, a soluble
inflammatory mediator, and C5b. C5b binds the target cell surface and C6
forming C5b6, which binds C7 (C5b-7) then C8. The C5b-8 complex binds C9
(C5b-9) and facilitates polymerization of several additional C9 proteins.
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Figure 4. 2.

Activation and regulation of complement pathways relevant to
Borrelia spp. infection. Points of complement inhibition
utilized by Borrelia spp. are indicated by red octagons. (A)
Classical pathway. (B) Mannose-lectin pathway. (C)
Alternative pathway. Red arrows indicate borrelial proteins
that interact with a host regulatory protein.
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These polymerized C9 proteins form the transmembrane pore of the MAC
allowing an influx of extracellular fluid and subsequent lysis of the target cell.
The lectin pathway is very similar to the classical pathway, differing
only in the initiation steps. The lectin pathway is typically initiated through
mannose-binding lectins, a group of pattern recognition receptors (PRRs) on
host cells, binding specific sets of carbohydrates on foreign cells (pathogenassociated molecular patterns, PAMPs). The lectin and classical pathways
converge at the cleavage of C2 and C4 by different mechanisms. In the lectin
pathway, C4 and C2 cleavage occurs through mannose-binding lectinassociated serine proteases (MASPs) (316).
Like the classical and lectin pathways, the alternative pathway forms a
C3 convertase, C5 convertase, and results in the formation of the MAC.
Unlike the classical and lectin pathways, the alternative pathway may not
require antibody-antigen or PAMP-PRR interactions for activation. Rather, this
pathway is initiated through hydrolysis of C3 to C3(H2O), which is thought to
occur continuously at low levels. The pathway is propagated through
interactions with bacterial antigens or a lack of host surface markers (e.g.
sialic acid, glycosaminoglycans, sulfated polysaccharides) (316).
Factor B, after binding C3(H2O), is cleaved by factor D into Ba and Bb
resulting in C3(H2O)Bb, the fluid-phase C3 convertase (cleaves C3 to C3a
and C3b). C3b binds the bacterial cell surface where it complexes with
additional factor B. Factor D again cleaves factor B, which results in the
second, predominant and cell-bound C3 convertase (C3bBb). This cell-bound
C3 convertase is stabilized by properdin (C3bBbP). Binding of additional C3b
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to C3 convertase results in the formation of C5 convertase (C3bBbC3b),
which cleaves C5 and initiates the formation of the MAC as described above.
Inhibition of the Mammalian Complement System
by Borrelia and Ixodes
Regulation of complement is critical for the survival of host cells (320,
321). Numerous mechanisms have evolved in hosts to prevent aberrant
activation of complement on host cells including the use of complement
regulatory factors and host cell surface components (e.g. sialic acid).
Pathogens that inhibit host complement use mechanisms that are
inextricably tied to host regulatory processes. Borrelia use several native
proteins to inhibit complement (i.e. factor H-binding proteins or CRASPs,
p43, BBK32, BGA66, BGA71, CD59-like protein) (322). The following sections
focus on the complement regulators factor H (FH), factor H-like protein-1
(FHL-1), factor I (FI), C4-binding protein (C4bp), and CD59.
At least for Lyme borreliae, resistance to complement varies by strain
and species (115, 323–327). Roughly 10% of B. burgdorferi s.s. are serumresistant and 90% are intermediately resistant to serum; 75% of B. afzelii
isolates are resistant, 25% are intermediate; 100% of B. garinii isolates are
sensitive (specifically, OspA serotypes 3, 5, 6, 7); B. bavariensis (formerly B.
garinii OspA serotype 4) is intermediately resistant. To the best of our
knowledge, similar comparisons of multiple strains and species have not
been published for relapsing fever Borrelia, though complement resistance is
not universal among relapsing fever species among the strains observed.
Resistance to complement is important for the transmission, survival, and
dissemination of some Borrelia spp. in mammalian and rodent hosts and
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reservoirs (328). Infectious strains of Borrelia are masters of complement
evasion due to the native anti-complement proteins some possess and the
ability all infectious strains possess to co-opt tick and host complement
regulatory proteins.
Factor H, Factor H-Like Protein 1 (FHL-1), and Factor I
FH is an ubiquitous 150-kDa soluble protein produced by diverse cell
types throughout the human body (e.g. hepatic cells, fibroblasts, monocytes,
endothelial cells) (329). FH consists of 20 short consensus repeats, while
FHL-1 is a truncated variant of FH consisting of the FH N-terminal short
consensus repeats 1 through 7. Both FH and FHL-1 are major direct
regulators of the alternative complement pathway. In addition, FH and FHL-1
can directly regulate the classical and lectin pathways, though the regulatory
roles in these pathways are minor compared to other classical and lectin
regulatory mechanisms. Regulation is achieved through the recognition of
self and non-self molecules via domains located on the C- and N-terminals,
respectively (330–332). The C-terminal discriminates self from non-self
through interactions with sialic acids, glycosaminoglycans, and sulfated
polysaccharides, which are typically found only on host cells (333–337). FH
binds self-molecules with high affinity to prevent activation of complement.
FH regulates the classical and lectin pathways by acting as a co-factor for FI.
In this capacity, FH facilitates the serine protease activity of FI in cleaving
and inactivating C3b. The alternative pathway is regulated through FH
targeting factor Bb, which prevents the formation of fluid-phase C3
convertase and promotes decay (“decay acceleration activity”) of C3 and C5
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convertases (338). For comprehensive reviews of FH and FHL-1 see
references (329, 338, 339).
Factor H-Binding Proteins and CRASPs
Interactions with FH are the best-studied mechanism for Borrelia
complement inactivation and complement resistance is correlated with
binding FH (114). Borrelia spp. bind FH and/or FHL-1 through various native
proteins collectively termed factor H-binding proteins (FHBPs) or
Complement Regulator-Acquiring Surface Proteins (CRASPs) (115–117).
CRASPs can be grouped by their ability to bind only FH or both FH and FHL-1
as well as the species specificity of binding (that is, whether a FHBP can bind
FH from only one or several host species) (115, 117): CRASP-1 (CspA) and
CRASP-2 (CspZ) bind both FH and FHL-1, while CRASP-3 (ErpP), CRASP-4
(ErpC), and CRASP-5 (ErpA) bind only FH. CRASPs bind soluble FH and
maintain it in an active conformation thereby allowing FH to inhibit
completion of the complement response (i.e. MAC formation).
Several relapsing fever spirochetes bind FH in vitro (115, 340–345).
Two FHBPs, FhbA and BhCRASP-1, have been identified in B. hermsii strains
YOR and HS1, respectively (346, 347). However, binding FH is not as
important for relapsing fever spirochetes to establish infection as it is for
Lyme disease Borrelia (122, 123). Further supporting the non-essential
nature of binding FH, Woodman et al. (122) found that despite FhbA being
surface-exposed and strongly binding FH in vitro, only 16% of B. hermsii
recovered from the blood of infected mice had detectable levels of bound FH.
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C4b-Binding Protein
C4b-binding protein (C4bp) has regulatory roles in all three pathways,
though is the major regulator of the classical and lectin pathways. C4bp
facilitates inactivation of C4b (classical, lectin) and fluid-phase C3b
(alternative) by binding C4b, displacing C2a, and facilitating FI-mediated
inactivation of C3 and C5 convertases (348).
Some Lyme and relapsing fever Borrelia spp. bind human and various
animal C4bp (114, 342, 343, 349, 350). A comprehensive analysis identified
outer surface proteins associated with C4bp including OspA, Vlps, Vmps, and
several unidentified outer surface proteins (351). Other studies, however,
have observed no binding of C4bp by Borrelia spp. (114, 344, 352). These
contradictory data may be due to differences in experimental design
including the use of different strains, growth medium, temperatures, growth
phases, and the use of recombinant versus native human C4bp. A putative
C4bp receptor, p43, has been identified in B. burgdorferi s.l. (349). The
relapsing fever spirochetes B. recurrentis and B. duttonii produce CihC, a
surface lipoprotein homologous in sequence and function to fibronectinbinding proteins of other relapsing fever spirochetes, which also binds C4bp
(342).
FHBP, C4bp, and Borrelia Niche
Resistance to complement is positively correlated to the infectivity of
some Borrelia strains (327). With a higher resistance to complement, the
more likely a bacterium can survive, disseminate, and proliferate. Co-opting
tick proteins will protect spirochetes during the initial stages of transmission
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and dissemination but sustained dissemination requires Borrelia to resist
complement via its own native mechanisms.
This leads to the question of how complement sensitive strains can
cause infection. An interesting hypothesis was developed regarding
complement resistance and spirochete niche when a relationship was noted
between binding of the complement inhibitors, C4bp and FH (79, 349, 350).
Neurotropic strains (e.g. B. bavariensis, B. garinii, B. turicatae, B. duttonii,
and to a lesser extent B. hermsii) do not have to be highly resistant to
complement in immunoprivileged sites, such as the central nervous system.
Finding neurotropic species strongly bind C4bp and very weakly bind FH and
FHL-1, while species that are not neurotropic bind C4bp but preferentially
bind FH and/or FHL-1 supports this hypothesis (349). Alitalo et al. (353) did
find B. garinii strains isolated from neuroborreliosis patients not only express
FHBPs not expressed by strains cultured in vitro for an extended time, but
the FHBPs also bind FH. This implies complement-resistance, though this was
not reported and one of the isolates (LU59) was later reported to be highly
but not completely sensitive to complement (354). It is possible strong
binding of FH is an artifact seen in vitro, similar to that observed with
relapsing fever spirochetes (see section: Factor H binding proteins and
CRASPs). Thus, binding FH is not required for neurotropic strains. Perhaps
C4bp is sufficient to prevent complement activation during migration of
neurotropic species from the site of inoculation to immunoprivileged sites. On
the other hand, binding FH may be important for neurotropic strains to resist
complement during migration and the incomplete sensitivity observed by
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Sandholm et al. (350) may be due to in vitro culturing resulting in the
population losing its ability to bind FH. It could also be that neither C4bp nor
FHBPs play a role in complement-sensitive borreliae disseminating and a
novel mechanism is utilized by complement-sensitive strains.
CD59-Like Protein
Little information is available regarding the CD59-like protein of B.
burgdorferi. Pausa et al. (355) demonstrated an increase in serum sensitivity
and MAC formation in a serum-resistant B. burgdorferi isolate treated with
anti-CD59 antibodies compared to the control treated B. burgdorferi and the
serum-sensitive B. garinii isolate. In eukaryotic cells, CD59 is a surfaceexposed membrane protein that prevents C9 polymerization and thus the
formation of the MAC (19,20). Still, it is not clear Borrelia possesses a
protein homologous to mammalian or rodent CD59. While human anti-CD59
antibodies bound a surface-exposed integral membrane protein (29 kDa),
this protein has never been identified though several known borrelial proteins
can and have been ruled out based on molecular weight (e.g. BGA66,
BGA71, OspA, OspB, OspC) (322). Given the demonstrated complementresistance conferred by this unknown borrelial protein, more attention should
be given to identifying and clarifying the role this protein plays in
complement resistance.
Complement Inhibition by Ixodes
and Ornithodoros Salivary Proteins
A large number of proteins with a vast array of functions have been
identified in the saliva of feeding Ixodes spp. with more being identified and
characterized (106, 107, 356–358). While the details and mechanisms for
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some of these proteins remain to be elucidated, the beneficial nature of
Ixodes salivary proteins to spirochete transmission and survival has been
established (359–363, 274, 364, 365). Ixodes saliva contain adaptive and
innate immunomodulatory and anti-complement proteins (106, 108–113). A
recent study demonstrated changes in the salivary protein profile over the
course of a feeding, which has implications for the efficacy of the host
immune response at the feeding pit and for transmitting spirochetes (357).
Currently, several members of the anti-complement family of proteins have
been characterized from I. scapularis, I. ricinus, and I. persulcatus including
Salp15, Salp20, Isac, Irac I, Irac II, and Ixac-B1, -2, -3, -4, -5.
Salp15 is able to inhibit both adaptive and innate immune responses
(366, 367). Salp15 binds OspC, which both serum-resistant and serumsensitive B. burgdorferi s.l. produce, to inhibit deposition of the MAC and
block the recognition and binding of antibodies to OspC (361, 368–370). In
addition, Salp15 expression increases when ticks are infected with B.
burgdorferi (361). Interestingly, mice passively immunized with anti-Salp15
antibodies were protected from infection with B. burgdorferi (371).
Salp20 inhibits the alternative complement pathway through binding
properdin, which prevents stabilization of C3 convertase and propagation of
the alternative pathway (113, 372, 373). In addition, Salp20 enhances the
activity of factor H to inhibit the alternative pathway (113). Incubating a
serum-sensitive B. garinii strain with Salp20 protected the strain from
complement activation and lysis (372). The mechanism(s) by which Salp20
confer(s) protection to B. garinii is unknown.
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The Isac-like family of proteins includes Isac (Ixodes scapularis
anticomplement), Irac I (I. ricinus anticomplement), Irac II, and Ixac-B1
through -5 (I. ricinus anticomplement). Proteins in this family are similar in
function to Salp20 (110, 112, 374). Inhibition of the alternative complement
pathway is achieved through targeting C3 convertase via interactions with
properdin, as Salp20 does, and by preventing factor B from binding C3b or
displacing factor B from C3 convertase.
Ornithodoros salivary gland extracts also possess proteins that inhibit
the host immune response (118). To date, however, one complement
inhibitor has been identified and characterized from one Ornithodoros spp. O.
moubata, found in Africa, is the vector of the relapsing fever spirochete B.
duttonii (119). O. moubata complement inhibitor (OmCI) is a lipocalin that
binds to and prevents cleavage of C5 (120, 121). OmCI was found to be
effective at inhibiting C5 cleavage in different mammalian and rodent hosts
(121). It is unknown if OmCI protects B. duttonii or if homologous proteins
are found in other Ornithodoros spp.
Purpose
In this study, we investigated the acquisition of B. miyamotoi by larval
I. scapularis and found B. miyamotoi is efficiently acquired by uninfected
larval I. scapularis and maintained through the molting process. Unlike other
relapsing fever Borrelia (75), B. miyamotoi does not appear to be specific to
an Ixodes spp. In addition, we found B. miyamotoi binds human factor H in
vitro and a potential effect of mouse age on the duration of infection in
immunocompetent C3H/HeN.
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Methods
B. miyamotoi
An original Japanese strain of B. miyamotoi, FR64b, was kindly sent
from Dr. Robert Gilmore (Centers for Disease Control, Fort Collins, CO)
(chromosome sequence available under NCBI Reference Sequence ID
NZ_CP004217.2).
Culture Conditions
B. miyamotoi FR64b and mouse blood were cultured in MKP-F medium
at 34°C with 5% CO2 in capped Falcon tubes (8 or 16 mL), 1 mL deep-well
96-well plates sealed with silicone mat lids, or microcentrifuge tubes (1.5 or
2.0 mL) (314). Rifampicin (50 µg/mL) and phosphomycin (20 µg/mL) was
added when appropriate. For growth curves, B. miyamotoi was cultured for
four days in MKP-F medium at 34°C + 5% CO2. Cultures were then diluted
1:100 into fresh MKP-F, incubated at 34°C + 5% CO2. Total cells (i.e. motile
and non-motile) were counted every 24 hours using a Petroff-Hausser
Counting Chamber (Cat # 3900; Hausser Scientific, Horsham, PA). Cultures
were diluted in 1X PBS when appropriate to facilitate accurate cell counts.
Serum Sensitivity
Ten mL of 107 B. miyamotoi were centrifuged at 6000 x g for 15 min
at room-temperature. Pellets were washed once with 1X PBS, resuspended in
10 mL filter-sterilized normal human serum (NHS), and incubated at 34°C +
5% CO2 for 27.5 hours. To verify spirochetes were still alive after transfer to
human serum donated by Dr. Travis Alvine, 10 µL was viewed under
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Darkfield. After incubation, the presence of motile spirochetes was
determined by placing 10 µL on a slide and viewing 10 fields under Darkfield.
Factor H Binding
1 x 106 B. miyamotoi were harvested by centrifugation and
resuspended in 100 µL veronal buffered saline supplemented with 1mM Mg2+,
0.15mM Ca2+, and 0.1% gelatin. Normal human serum (NHS) was incubated
with 0.34 M EDTA to inhibit complement activation. The cell suspension was
incubated with 1.5 mL NHS for 1 hour, washed with PBSA, and then proteins
bound to the cells were eluted with 0.1 M glycine-HCL, pH 2. Cells were
removed by centrifugation and the supernatant was analyzed by Western
blotting with a mouse monoclonal anti-human Factor H antibody (Quidel).
One µg recombinant human Factor H (aa 860-1231; ~65kDa on SDS-PAGE;
R&D Systems) was used a positive control.
Mouse Infections
Two to four week-old Rag1-/- C57BL/6J mice and 2-4 week-old and 6-8
week-old C3H/HeN were infected by intraperitoneal injection of 107
spirochetes. Blood was collected from saphenous veins every 12 hours for
two weeks. Mice were subcutaneously injected with sterile 0.9% saline as
necessary. The collected blood was immediately added to 90 µL 0.11 M
sodium citrate solution, pH 7.2. Spirochetes were cultured by adding 10 µL of
diluted blood to 1 mL prewarmed MKP-F. The remaining blood solution was
stored at -20°C for DNA isolation.
Four mice of strains 129S1, C57BL/6J, C57BL/10J, NOD/ShiLtJ, SJL,
CBA/CaJ, DBA/1J, DBA/2J, A/J, BALB/cJ, CBA Jackson, and FVB/NJ (3-4
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weeks old) were infected subcutaneously with 107 B. miyamotoi FR64b. Blood
was collected from saphenous veins every 24 hours for two weeks and
cultured as described above. Four weeks after infection, mice were perfused
with 1X PBS. Blood, ear pinnae, brain, thymus, heart, lungs, liver, pancreas,
spleen, kidneys, bladder, and tibiotarsal joints were collected for PCR and
culture.
To determine the minimum infectious dose, groups of three 4-6 weekold C3H/H3N mice were infected subcutaneously with the following doses of
B. miyamotoi FR64b: 101, 102, 103, 104, or 10
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spirochetes. Blood was

collected every 24 hours as described above.
Ixodes scapularis Feeding
Uninfected larval I. scapularis were obtained from the Centers for
Disease Control (Atlanta, GA). Uninfected larvae were fed to repletion on
infected Rag1-/- C57BL/6J. Replete larvae were collected once per day. One
to ten larvae per day were collected, placed in 70% ethanol, and stored at
4°C for DNA isolation and PCR. The remaining larvae were stored in vented
conical tubes in a 95-99% humidified chamber at 23°C to molt. Ten larvae
were collected once per week throughout the molting process. One week
after molting, three flat nymphs were collected, placed in 70% ethanol, and
stored at 4°C for DNA isolation and PCR.
DNA Isolation and PCR from Ixodes Larvae and Nymphs
I. scapularis DNA was isolated by modifying a previous protocol (59).
Ticks stored in 70% ethanol were dried at room temperature overnight. Ticks
were crushed in 600 µL of buffer ATL (Qiagen). 20 µL proteinase K (Qiagen)
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was added. Tubes were vortexed briefly and incubated overnight at 56°C.
Tubes were briefly vortexed and incubated at 56°C for an additional 2 hours
then centrifuged at maximum speed for 3 minutes at room temperature.
Supernatants were transferred to a clean microcentrifuge tube. Ethanol
precipitations were performed using 1/10 volume 3 M sodium acetate and
3 volumes 95% ethanol. Samples were incubated overnight at -20°C then
centrifuged at maximum speed for 30 minutes at 4°C. Ethanol was decanted,
and the pellet was resuspended in 1 mL nuclease-free water. If necessary,
resuspension of the pellet and salt was facilitated by incubating the tube at
56°C. Samples were filtered through a Microcon DNA Fast Flow Centrifugal
Filter Unit (Millipore). The filter membrane was washed once with 500 µL
nuclease-free water. DNA was eluted twice with 100 µL nuclease-free water.
Purified DNA was stored at 4°C overnight for use in PCR.
PCR was performed with primers for TROSPA
(F: GTTGCTGTCCATGCTG; R: AAGTGTTCGTTTCCCTTT),
bipA (F: AAATCCAGGAAATGTTGATG; R: GCCACCAGACTTAATAGCAC), and
oppA1 (F: ACTCAAATGAAGTAGAATTAGAAGAG; R:
GTAAGCGTTTCTCTGTCAATAG) using Platinum PCR SuperMix High Fidelity
(ThermoFisher). For each reaction, 200 nM of each primer and 1 µL of DNA
was added to 45 µL of Platinum PCR SuperMix and the following PCR cycle
was performed: 94°C for 2 min, 45 cycles of 94°C for 15 sec, 50°C for 30
sec, 68°C for 15 sec. Ten µL of each reaction was run on a 2% TBE gel and
stained with ethidium bromide.
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Rosetting Erythrocytes
The ability of B. miyamotoi FR64b to rosette human erythrocytes was
tested as previously described (375, 376). Briefly, B. miyamotoi FR64b and
B. burgdorferi MI-16 were cultured to approximately 106 spirochetes/mL. Red
blood cells were separated and diluted to a final concentration of 5% in RPMI.
The remaining whole blood was diluted 1:10 in 1X PBS. Four and six mL of B.
miyamotoi and B. burgdorferi were centrifuged and resuspended in 500 µL
diluted whole blood or RPMI. For one protocol, 5% erythrocytes and
resuspended Borrelia were incubated separately for 15 minutes at 37°C.
Erythrocytes and Borrelia were mixed at a 1:1 or 2:1 ratio then placed on a
glass slide with a coverslip and sealed with clear nail polish. Slides were then
incubated for 15 minutes at 23°C or 37°C. Slides were viewed under
Darkfield immediately after incubations. For a second protocol, Borrelia were
resuspended in diluted whole blood, placed on a glass slide, covered, and
sealed with clear nail polish. Slides were incubated for 30 minutes at 23°C
and 37°C then viewed under Darkfield.
Results
Growth of B. miyamotoi
B. miyamotoi was grown in modified MKP-F medium to assess the
growth rate (Fig. 4.3). Generation time at 34°C + 5% CO2 is approximately
16 hours, slightly longer than B. burgdorferi with a generation time of 8-12
hours. Maximum cell density peaked at approximately 5 x 107
spirochetes/mL, again, slightly lower than B. burgdorferi, which reaches a
maximum density of approximately 108 spirochetes/mL. Growth curves were
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Figure 4. 3.

Growth of B. miyamotoi in modified MKP-F medium.
Spirochetes were counted every 24 hours. Generation time is
approximately 16 hours and peak density is approximately
5 x 107 cells/mL.

not performed at 23°C or 37°C, however, B. miyamotoi did grow at both
temperatures.
Minimum Infectious Dose and the Effect
of Mouse Strain on Infection
None of the cultures from C3H/HeN mice infected with different
concentrations of B. miyamotoi were positive. As we have successfully
infected C3H/HeN mice with B. miyamotoi, negative cultures represent either
mice were not sufficiently infected or there was a problem with the medium.
One blood sample obtained at 24 hours for each of the 129S1, C57BL/6J,
C57BL/10J, NOD/ShiLtJ, SJL, CBA/CaJ, DBA/1J, DBA/2J, A/J, BALB/cJ, CBA
Jackson, and FVB/NJ mice was viewed via microscopy and showed viable
spirochetes. Unfortunately, subsequent cultures were also negative.
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B. miyamotoi Resists Human Serum
and Binds Human Factor H
B. miyamotoi was incubated with normal human serum (NHS).
Immediately after resuspending spirochetes in NHS, no dead spirochetes
were observed. This was important to ensure spirochetes were not killed
during transfer and resuspension in NHS. Spirochetes were incubated for
27.5 hours, after which, ten random fields were observed with Darkfield
microscopy. Motile spirochetes were observed in all fields showing B.
miyamotoi is resistant to human serum.
Sequence alignments revealed a putative factor H binding protein
homologous to factor H binding proteins of other relapsing fever spirochetes
(B. turicatae, B. parkeri, and B. hermsii) (Fig. 4.4). B. miyamotoi was
incubated with normal human serum to determine whether it binds human
factor H. Proteins bound to the surface of B. miyamotoi were removed and
analyzed via Western blot using anti-human factor H antibodies (Fig. 4.5). A
band of approximately 65 kDa is visible in the eluate fraction, demonstrating
human factor H was bound by B. miyamotoi.
Infection by Needle Inoculation is Detectable 12 Hours
Post-Infection in Rag1-/- C57BL/6J
and Immunocompetent C3H/HeN Mice
Spirochetes were visible in wet whole blood mounts in all six mice 24 hours postinfection (hpi) (Fig. 4.6). However, all mice were positive by culture 12 hpi (Table 4.1).
Rag1-/- mice became persistently infected, whereas the 3-4 week-old C3H/HeN mice
were negative by culture 96 hpi. Blood was not routinely collected from Rag1-/- mice after
144 hpi. Even with saline injections, it became difficult to collect blood every 12 hours.
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As a result, blood was collected from these mice at 252 and 336 hpi. The 6-8 week-old
C3H/HeN mice were positive by culture 12 to 72 hpi. Both mice were negative by
culture at 84 hpi but one mouse produced a positive culture 96 hpi, while the
other mouse produced a positive culture 144 hpi.

Figure 4. 4.

Protein alignment shows homology between a putative factor
H binding protein in B. miyamotoi and factor H binding
proteins from B. turicatae, B. parkeri, and B. hermsii.
Identical residues are highlighted in bright yellow and
denoted with an asterisk. Residues strongly sharing similar
biochemical properties are highlighted in light yellow and
denoted with a colon. Residues weakly sharing similar
biochemical properties are denoted with a period.

Figure 4. 5.

B. miyamotoi binds human factor H. Recombinant human
factor H (rhFH) is approximately 65 kDa. A band of similar
size is present in the B. miyamotoi eluate fraction.
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Figure 4. 6.

Table 4. 1.

Spirochetes were detected in whole blood mounts 24 hpi in all
six mice. Three representative images are shown. (A) Rag1-/C57BL/6J, (B) C3H/HeN, 2-4 week-old, (C) C3H/HeN, 6-8
week-old.
Presence of spirochetes determined from culture and/or microscopy.

Time (h)

Rag1-/- C57BL/6J 2-4
WT C3H/HeN 2-4 wo
wo
0
-a
12
+b
+
+
+
24
+
+
+
+
36
+
+
+
+
48
+
+
+
+
60
+
+
+
+
72
+
C
+
+
84
+
+
+
+
96
+
+
108
+
+
120
+
+
132
+
+
C
144
+
+
156
NCd
NC
168
NC
NC
180
NC
NC
C
C
192
NC
NC
204
NC
NC
216
NC
NC
228
NC
NC
240
NC
NC
252
+
+
264
NC
NC
276
NC
NC
288
NC
NC
300
NC
NC
312
NC
NC
324
NC
NC
336
+
+
a
No spirochetes detected by microscopy or culture
b
Spirochetes observed by microscopy and/or culture
c
Culture contaminated
d
No blood collected
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WT C3H/HeN 6-8 wo
+
+
+
Cc
+
+
+
-

+
+
+
+
C
+
+
C
-

B. miyamotoi does not Appear to be Vector-Specific or Exclusive
To determine whether B. miyamotoi is specific to an Ixodes spp.,
North American I. scapularis larvae were fed to repletion on infected Rag1-/mice infected with a Japanese strain of B. miyamotoi (FR64b). B. miyamotoi
FR64b was isolated from Apodemus argenteus (small Japanese field mouse)
but is vectored by I. persulcatus (20). If B. miyamotoi is exclusive to its
respective vector, we would not expect a Japanese strain to survive in North
American I. scapularis. DNA extracted from I. scapularis larvae was positive
for bipA immediately after feeding and in the weeks leading up to molting
(Fig. 4.7). A faint PCR band is present for ticks collected from mouse 2 (M2)
on the first day replete ticks began dropping (D1) (Fig. 4.7A). Importantly, I.
scapularis were positive for bipA after molting to nymphs meaning B.
miyamotoi is able to establish an infection in I. scapularis and survive the
molting process (Fig. 4.7C). This suggests B. miyamotoi is not exclusive to
one Ixodes spp.
Rosetting Erythrocytes
To determine whether B. miyamotoi is capable of rosetting
erythrocytes like some relapsing fever Borrelia, B. miyamotoi was incubated
with whole blood and purified erythrocytes. No erythrocyte rosetting was
observed under any conditions used (Fig. 4.8).
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Figure 4. 7.

B. miyamotoi DNA was detected in I. scapularis throughout
and after the molting process. PCR was performed for the
tick-specific TROSPA gene, the relapsing fever-specific bipA
gene, and the Lyme Borrelia-specific oppA1 gene. bipA was
detected in each tick sample except M1 week 2 and 4. oppA1
was not detected in any tick samples analyzed showing the
ticks and mice are not infected with B. burgdorferi. D1: Day
1, first day replete ticks fell off each mouse; M1: mouse 1,
M2: mouse 2; W1: week 1, one week after ticks were
collected; B. miya: B. miyamotoi genomic DNA, B. burg: B.
burgdorferi genomic DNA, NTC: no DNA template added.
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Figure 4. 8.

B. miyamotoi does not appear to rosette erythrocytes.
B. miyamotoi was incubated 1:1 with 5% purified
erythrocytes at 23°C. Similar results were observed at 37°C,
with whole blood, at 1:2 (B. miyamotoi:erythrocytes) ratios,
and with B. burgdorferi.
Discussion

We can develop effective treatment and prevention methods by
understanding the mechanisms by which a pathogen causes disease.
Modeling human infection in the laboratory is difficult. Various animals can
model isolated aspects of disease but generally fall short of recapitulating a
complete human disease. To gain a full understanding of a human pathogen
requires patching together several pieces of information, such as identifying
virulence factors. An additional method to assess a pathogen’s ability to
establish an infection is by determining serum susceptibility; a pathogen
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susceptible to human sera will likely not be able to establish infection in
humans (328, 377). B. miyamotoi has previously been shown to resist
human serum (171, 172), however, complement resistance varies by strain
and species with B. burgdorferi s.l. species (115, 323–327). Without a
complete history for the strain and culture of B. miyamotoi used in our lab,
we verified serum resistance for B. miyamotoi FR64b.
We showed B. miyamotoi FR64b possesses a putative FHBP and is
capable of binding human factor H in vitro (Fig. 4.4, Fig. 4.5). Whether B.
miyamotoi binds factor H in vivo and is a biologically relevant function
remains to be determined. Species of the B. burgdorferi s.l. complex rely
heavily on complement inactivation to establish an infection, while relapsing
fever Borrelia do not (122, 123). Still, several relapsing fever Borrelia
possess FHBPs (346, 347) and bind factor H in vitro (115, 122, 340–345).
This begs the question if binding factor H is not biologically relevant for
relapsing fever Borrelia, why maintain FHBPs? FHBPs are located on plasmids
in B. burgdorferi and while significant rearrangement has occurred between
plasmids across strains, the content has remained relatively unchanged (23).
That is, B. burgdorferi moves genes around but has not removed or added
genes. In addition, the FHBP found in relapsing fever Borrelia, FhbA, is also
found on a plasmid, which is also stable (123, 346, 347). Species of the B.
burgdorferi s.l. complex maintain numerous FHBPs but only one, FhbA and
homologs, has been identified in relapsing fever Borrelia (123, 346).
Perhaps, despite plasmid stability, relapsing fever Borrelia once had but has
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since lost several FHBPs from their genomes and FhbA may be on the
genomic chopping block.
Mechanisms of Immune Evasion by B. miyamotoi:
Where We Are
Given the genetic similarity of B. miyamotoi to relapsing fever
spirochetes, it is likely B. miyamotoi utilizes some homologous mechanisms
to evade host immune responses. While B. miyamotoi is resistant to
complement in vitro (171, 172), complement inactivation is not required for
relapsing fever spirochetes to establish infection. OspE homologues have
been identified in B. miyamotoi FR64b (isolated from the blood of A.
argenteus) however, McDowell et al. were unable to demonstrate FH-binding
(115). This suggests, as is the case for relapsing fever spirochetes,
inactivation of complement may not be required to resolve spirochetemia
during infection with B. miyamotoi (126, 174).
Instead, it appears B. miyamotoi utilizes a Vmp system (175) and
Wagemakers et al. (176) recently demonstrated antigenic variation of Vmps
in B. miyamotoi. C3H/HeN mice infected with B. miyamotoi LB-2001
produced anti-Vsp1 IgM and IgG antibodies that were effective in clearing the
initial spirochetemic peak of B. miyamotoi from SCID mice. Despite this
clearing, a second spirochetemic relapse occurred. Analyses of the secondary
B. miyamotoi population revealed expression of vlpC2, not vsp1, as would be
expected in the case of antigenic variation. They also noted vlpC2 was
present in the initial B. miyamotoi population in a much lower prevalence
compared to vsp1.
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An additional mechanism some relapsing fever Borrelia use to evade
host immune responses is by rosetting erythrocytes or coating the outer
membrane in erythrocytes (375, 376, 378). Infection with species capable of
rosetting erythrocytes, B. duttonii and B. crociduriae, is generally more
severe than infection with species unable to rosette erythrocytes (378, 379).
In addition to shielding Borrelia from an immune response, rosetting
erythrocytes can result in microemboli and tissue damage (379, 379). The
apparent inability of B. miyamotoi to rosette erythrocytes may, at least in
part, explain the decreased severity of B. miyamotoi infection in
immunocompetent patients.
Mechanisms of Immune Evasion by B. miyamotoi:
Where We Need to Be
Even though B. miyamotoi is genetically similar to relapsing fever
spirochetes, it has evolved and exists in different vectors (Ixodes not
Ornithodoros) with different enzootic cycles and different co-pathogens
compared to relapsing fever spirochetes. We should not assume B.
miyamotoi utilizes the same set of mechanisms as other relapsing fever
spirochetes. B. miyamotoi may use a combination of relapsing fever and
Lyme Borrelia mechanisms as well as completely novel mechanisms. There
are many open questions regarding how B. miyamotoi evades host responses
and establishes infection.
The role of IgM in clearing B. miyamotoi has not been demonstrated.
As discussed above, IgM is key in clearing relapsing fever infections. During
B. hermsii infections, IgM targets FhbA and other surface proteins (131). IgM
likely is important in clearing B. miyamotoi. All immunocompromised patients
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diagnosed with a B. miyamotoi infection developed meningoencephalitis. A
shared factor with these patients has been treatment with rituximab, a
monoclonal anti-CD20 antibody targeting IgM-producing CD20-positive B
cells. Depletion of B cells may explain how B. miyamotoi is able to migrate to
the CNS and causes meningoencephalitis in patients treated with rituximab.
The presence of unknown complement inhibitors, however, could contribute
to the complement-resistance of B. miyamotoi and may be useful in
establishing infection (171, 172).
The effects of tick saliva on B. miyamotoi survival have not yet been
studied. However, being vectored by Ixodes, B. miyamotoi likely takes
advantage of the protective proteins in tick saliva. In addition, understanding
interactions between host, vector, and pathogen will aid in the development
of Lyme and relapsing fever prevention strategies and thus requires more
attention.
Needle Infection
Via intraperitoneal injection, Rag1-/- C57BL/6J mice became
persistently infected, as expected. These mice lack mature B cells, which are
the cells responsible for mounting a response to other relapsing fever
Borrelia and provide an alternative immunodeficient mouse model to severe
combined immunodeficiency (SCID) mice (125–127, 129–131, 317–319).
Also, as expected, the C3H/HeN mice became infected. Wagemakers et al
(176) had previously infected 6-8 week-old C3H/HeN mice and shown
spirochetes were detected at 24 hpi. They also found three of eight mice had
a brief relapse at 6 and 7 dpi. This lead us to wonder whether the age of the
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mouse affected the duration and/or recurrence of spirochetemia since as with
humans, mice show deterioration of the immune system as they age (380).
Indeed, no recurrent spirochetemia was observed in young
immunocompetent C3H/HeN mice (Table 4.1). A brief spirochetemic event
was observed in older immunocompetent C3H/HeN mice (Table 4.1). It is
possible the 6-8 week-old mice did not experience a relapse and the negative
cultures observed were due to inadequate culturing. If this is true, the older
mice were still infected longer than the 2-4 week-old mice. DNA isolation
and PCR of blood during this potential clearing event would clarify these data.
Unfortunately, DNA isolation failed.
Limitations of Needle-Infection
There are several inherent limitations to be considered. The use of
needle infections as this is a less desirable method to replicate tick-borne
infections. In addition to being an artificial method to introduce Borrelia,
spirochete physiology and adaptation to a host can be negatively impacted.
Tick saliva is known to contain factors that help B. burgdorferi in establishing
infections in hosts (106–113, 274, 356–365). However, needle infections, if
successful, represent the most efficient method for introducing Borrelia to a
host for additional experiments. In addition, injection site can affect disease
pathology in mice when infecting with B. burgdorferi (381). For example,
subcutaneous injections of B. burgdorferi near the hind end of a mouse
results in more severe joint pathology. Whether the pathology of relapsing
fever is affected by injection site is unknown. Injection site may not affect B.
miyamotoi disease progression considering B. burgdorferi establishes
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persistent infections in tissues while relapsing fever Borrelia are mainly
blood-borne pathogens. Still, it is important to keep in mind that hosts will
not be exposed to Borrelia (Lyme or relapsing fever) by an intraperitoneal
tick bite.
Multiple methods should be used to confirm infection results. A
negative culture or blood smear does not mean an infection has cleared. One
2-4 week-old C3H/HeN mouse was negative by microscopy but positive by
culture at 84 hpi.
Vector Specificity
Tick-borne relapsing fever Borrelia demonstrate strong vector
exclusivity. For example, B. hermsii cannot establish an infection in any
Ornithodoros spp. besides O. hermsi. The reason for this specificity is
unknown but does appear to be universal among the soft tick-borne Borrelia.
Analyses have shown B. miyamotoi forms regional clades or group types (85,
86, 382). The exact groupings are still in flux as more researchers obtain
field-caught ticks and sequence B. miyamotoi. It appears a slightly different
strain of B. miyamotoi is carried by each species of Ixodes (vector
specificity). For example, strains of B. miyamotoi found in I. scapularis is
slightly different than strains found in I. pacificus, I. ricinus, or I. persulcatus
but strains found in I. scapularis are highly similar to each other. However,
dissimilarity in sequences should not automatically translate to vector
specificity. It can be difficult to test vector specificity in the US as it can be
difficult to obtain either European and Asian Borrelia or Ixodes. Through
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sheer luck, we were able to investigate vector specificity using a Japanese
strain of B. miyamotoi and North American I. scapularis.
PCR demonstrated B. miyamotoi DNA was present in Ixodes
immediately after feeding and in the weeks leading up to the molt (Fig 4.2).
Acquisition, however, is not sufficient to determine vector specificity. The
presence of Borrelia DNA or ability to culture Borrelia from a tick before
molting only demonstrates the spirochete was present in the host. For
Borrelia to establish an infection in ticks it must survive the tick molting, a
process during which the blood meal is digested and the tick undergoes a
traumatic restructuring process (47, 383).
Detecting B. miyamotoi DNA is flat nymphs confirms the Rag1-/- mice
were infected (Fig 4.1 and 4.2). It also demonstrates B. miyamotoi is
acquired by feeding ticks and survives the tick molting suggesting B.
miyamotoi can establish an infection.
Concluding Remarks
Although B. miyamotoi is similar to other relapsing fever Borrelia, it
has evolved, adapted, and exists in dramatically different vectors with
different enzootic cycles and different co-pathogens. In addition, infection
with B. miyamotoi in immunocompromised patients generally results in nonspecific symptoms (e.g. headache, malaise), recurrent fever, and
spirochetemia characteristic of relapsing fever. However, additional
symptoms characteristic of relapsing fever have not been demonstrated,
namely rapid symptom onset with a crisis event. This suggests B. miyamotoi
infection is not synonymous with relapsing fever and is, rather, a relapsing
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fever-like illness (90). The cause of this slightly different disease pathology is
unknown but there is no doubt the different lifestyle of B. miyamotoi plays a
role. Though the differences between B. miyamotoi and other relapsing fever
spirochetes identified thus far are minor, we should exercise caution and not
assume B. miyamotoi is like other relapsing fever Borrelia.
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pg. 1

Bacteria; Various
terrestrial and aquatic
environments
Protozoa; Causative
agent of STD
trichomoniasis

Acidobacteria

Trichomonas
vaginalis
Bacteria; Marine, aquifer
metagenome

Animal; Purple sea
urchin

Bacteria; Fish pathogen
Bacteria; Groundwater
metagenome

Lentisphaerae

Strongylocentrotus
purpuratus

Tenacibaculum sp.

Unknown

None

Additional Organism
Information
Synthetic ANK motif

Organism

hypothetical protein
A2283_08585
[Lentisphaerae
bacterium RIFOXYA12_
FULL_48_11]
PREDICTED:
serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit B-like
[Strongylocentrotus
purpuratus]
hypothetical protein
[Tenacibaculum sp.
4G03]
hypothetical protein
UR12_C0049G0006
[candidate division TM6
bacterium GW2011_
GWF2_30_66]

Chain A, 4ank: A
Designed Ankyrin
Repeat Protein With
Four Identical
Consensus Repeats
hypothetical protein
CSA81_06935
[Acidobacteria
bacterium]
hypothetical protein
[Trichomonas vaginalis
G3]

NCBI Description

52%

33%

44%

57%

42%

63%

Query
Coverage
47%

Appendix A
Table 1. Additional alignment information from blastp results of BB0399

33%

42%

33%

27%

35%

28%

Identity
to Query
29%

2e-08

2e-08

2e-08

1e-08

1e-08

9e-09

E
value
4e-09

KKP25019.1

WP_099213746.1

XP_011672323.1

OGV66031.1

XP_001326093.1

PIE02542.1

GenBank
Accession
1N0R_A
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Animal; Brown
anemone, glass
anemone, pale anemone
Animal; Brown
anemone, glass
anemone, pale anemone
Animal; Brown
anemone, glass
anemone, pale anemone
DNA virus; Amoeba
hosts

Aiptasia pallida
(Exaiptasia pallida)

Aiptasia pallida
(Exaiptasia pallida)

Aiptasia pallida
(Exaiptasia pallida)

Acanthamoeba
polyphaga mimivirus

Bacteria; Aquifer
metagenome

Unknown

Protozoa; Causative
agent of STD
trichomoniasis

Bacteria; Groundwater
metagenome

Unknown

Trichomonas
vaginalis

Animal; Brown
anemone, glass
anemone, pale anemone

Aiptasia pallida
(Exaiptasia pallida)

putative ankyrin repeat
protein [Acanthamoeba
polyphaga mimivirus]

putative ankyrin repeat
protein MM-0045
[Exaiptasia pallida]

uncharacterized protein
LOC110238015 isoform
X1 [Exaiptasia pallida]

uncharacterized protein
LOC110238015 isoform
X2 [Exaiptasia pallida]

Serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit B
[Exaiptasia pallida]
hypothetical protein
UR12_C0053G0001
[candidate division TM6
bacterium
GW2011_GWF2_
30_66]
hypothetical protein
A3F66_04490
[candidate division TM6
bacterium
RIFCSPHIGHO2_12_FU
LL_32_22]
ankyrin repeat protein
[Trichomonas vaginalis
G3]

49%

56%

63%

63%

65%

57%

73%

75%

32%

32%

30%

30%

29%

31%

28%

29%

9e-08

9e-08

7e-08

7e-08

7e-08

4e-08

4e-08

3e-08

YP_003986769.1

KXJ20897.1

XP_020899305.1

XP_020899308.1

XP_001318422.1

OGB84173.1

KKP24550.1

KXJ19934.1
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Bacteria; Groundwater
metagenome

Fish; Horned Goldenline barbel

Unknown

Sinocyclocheilus
rhinocerous

Insect; Bed bug

Cimex lectularius

Fungi; Causative agent
of chromoblastomycosis

Bacteria; Various
terrestrial and aquatic
environments

Acidobacteria

Cladophialophora
carrionii

DNA Mimiviridae virus;
Isolated from Hirudo
medicinalis leech (yep,
a medical leech)

Hirudovirus strain
Sangsue

DNA virus; Amoeba
hosts

Fungi; Anaerobic gut

Anaeromyces robustus

Acanthamoeba
castellanii mamavirus

DNA virus; Amoeba
hosts

Acanthamoeba
polyphaga mimivirus

hypothetical protein
CR997_04995
[Acidobacteria
bacterium]
PREDICTED:
tankyrase-1-like
[Cimex lectularius]
ankyrin repeatcontaining protein
[Acanthamoeba
castellanii mamavirus]
hypothetical protein
CLCR_07477
[Cladophialophora
carrionii]
hypothetical protein
UR12_C0053G0002
[candidate division
TM6 bacterium
GW2011_GWF2_
30_66]
PREDICTED: ankyrin1-like [Sinocyclocheilus
rhinocerous]

ankyrin repeatcontaining protein
[Acanthamoeba
polyphaga mimivirus]
ankyrin, partial
[Anaeromyces
robustus]
putative ankyrin repeat
protein [Hirudovirus
strain Sangsue]

65%

42%

56%

49%

48%

63%

49%

31%

49%

26%

34%

26%

31%

33%

27%

32%

42%

31%

3e-07

3e-07

2e-07

2e-07

2e-07

2e-07

2e-07

1e-07

1e-07

XP_016407777.1

KKP24551.1

OCT49800.1

AEQ60456.1

XP_014249139.1

PIE90600.1

AHA45596.1

ORX81127.1

AKI79037.1
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Animal; Brown
anemone, glass
anemone, pale
anemone
Fungi; Anaerobic gut

Bacteria; Marine
sediment

Aiptasia pallida
(Exaiptasia pallida)

Labilibacter marinus
(Saccharicrinis
marinus)
Animal; Marine lancelet

Animal; Brown
anemone, glass
anemone, pale
anemone
Animal; Brown
anemone, glass
anemone, pale
anemone
Insect; Elongate twig
ant

Branchiostoma belcheri

Aiptasia pallida
(Exaiptasia pallida)

Aiptasia pallida
(Exaiptasia pallida)

Pseudomyrmex gracilis

Piromyces sp.

Animal; Brown
anemone, glass
anemone, pale
anemone

Aiptasia pallida
(Exaiptasia pallida)

PREDICTED: ankyrin
repeat domaincontaining protein 50like [Branchiostoma
belcheri]
serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit B-like
[Exaiptasia pallida]
serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit B-like
[Exaiptasia pallida]
ankyrin-1-like isoform
X3 [Pseudomyrmex
gracilis]

hypothetical protein
[Labilibacter marinus]

hypothetical protein
PIROE2DRAFT_25186
[Piromyces sp. E2]

Serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit B
[Exaiptasia pallida]
uncharacterized
protein LOC110249705
[Exaiptasia pallida]

58%

62%

55%

44%

47%

49%

63%

64%

28%

30%

31%

31%

26%

32%

30%

30%

8e-07

8e-07

7e-07

6e-07

5e-07

4e-07

3e-07

3e-07

XP_020279924.1

XP_020894695.1

XP_020894601.1

XP_019622329.1

WP_083631127.1

OUM66985.1

XP_020911949.1

KXJ19941.1
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Bacteria; Bioreactor
metagenome

Animal; Brown
anemone, glass
anemone, pale
anemone
Animal; Japanese
scallop, Yesso scallop,
ezo giant scallop

Bacteria; Deep-sea
hydrothermal vents
Archaea; Hot springs
Fungi; Pathogenic,
mainly associated with
improperly stored food
grains and peanuts
Animal; Brown
anemone, glass
anemone, pale
anemone

Candidatus
Amoebophilus sp.

Aiptasia pallida
(Exaiptasia pallida)

Persephonella sp.

Thermofilum

Aspergillus parasiticus

Aiptasia pallida
(Exaiptasia pallida)

Mizuhopecten
yessoensis

Primate; Anubis
baboon, Olive baboon

Papio anubis

serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit A-like
[Exaiptasia pallida]

serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit C-like
[Mizuhopecten
yessoensis]
hypothetical protein
[Persephonella sp.
IF05-L8]
MULTISPECIES:
hypothetical protein
[Thermofilum]
hypothetical protein
P875_00042660
[Aspergillus parasiticus
SU-1]

LOW QUALITY
PROTEIN: ankyrin
repeat domaincontaining protein 7
[Papio anubis]
hypothetical protein
BGO68_01365
[Candidatus
Amoebophilus sp. 3638]
uncharacterized
protein LOC110251065
[Exaiptasia pallida]

56%

51%

42%

44%

68%

73%

39%

53%

30%

36%

34%

29%

24%

28%

34%

28%

1e-06

1e-06

1e-06

1e-06

1e-06

9e-07

9e-07

8e-07

XP_020913952.1

KJK61139.1

WP_020962764.1

WP_051654701.1

XP_021378548.1

XP_020913391.1

OJW67195.1

XP_009202018.2
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Fungi; Anaerobic gut
Bacteria; Isolate from
aquifer metagenome
but genus found in
various terrestrial and
aquatic environments,
animal gut
Insect; Parasitoid wasp
useful as a biocontrol
agent in agriculture

Piromyces finnis

Bacteroidetes

Animal; Pacific oyster,
Japanese oyster, Miyagi
oyster

Insect; Parasitoid wasp
useful as an biocontrol
agent in agriculture
Fungi; Anaerobic gut

Primate; Crab-eating
macaque
Insect; Redheaded pine
sawfly, Leconte’s sawfly

Magallana gigas
(Crassostrea gigas)

Microplitis demolitor

Piromyces sp.

Macaca fascicularis

Neodiprion lecontei

Microplitis demolitor

Bacteria; Groundwater
metagenome

Unknown

RecName:
Full=Ankyrin repeat
domain-containing
protein 7
PREDICTED:
ankycorbin [Neodiprion
lecontei]

PREDICTED: GAbinding protein subunit
beta-2 isoform X2
[Microplitis demolitor]
PREDICTED:
serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit C
[Crassostrea gigas]
PREDICTED: GAbinding protein subunit
beta-2 isoform X1
[Microplitis demolitor]
hypothetical protein
PIROE2DRAFT_31296
[Piromyces sp. E2]

Ankyrin-3 [candidate
division TM6 bacterium
GW2011_GWF2_
30_66]
ankyrin [Piromyces
finnis]
hypothetical protein
A2W98_07475
[Bacteroidetes
bacterium
GWF2_33_38]

47%

62%

39%

49%

54%

49%

42%

51%

42%

24%

29%

36%

26%

27%

26%

32%

35%

32%

2e-06

2e-06

2e-06

2e-06

2e-06

2e-06

2e-06

1e-06

1e-06

XP_015516779.1

Q4R3S3.1

OUM64010.1

XP_008549169.1

XP_011454531.1

XP_008549170.1

OFY18134.1

ORX41735.1

KKP25236.1
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Athalia rosae
Bacteria; Isolated from
patient with
Legionnaires’ disease,
but unable to replicate
in amoeba

Insect; Turnip sawfly

Athalia rosae

Legionella hackeliae

Primate; Green monkey

Chlorocebus sabaeus

Insect; Ant (if you made
it this far, you deserve a
bonus factoid: this
genus has no worker
caste)
Insect; Turnip sawfly

Bacteria; Groundwater
metagenome

Gallionellales

Vollenhovia emeryi

Primate; Sooty
mangabey

Cercocebus atys

GA-binding protein
subunit beta-2 isoform
X3 [Athalia rosae]
hypothetical protein
[Legionella hackeliae]

PREDICTED: ankyrin
repeat domaincontaining protein 7
[Cercocebus atys]
hypothetical protein
COZ77_10025
[Gallionellales
bacterium
CG_4_8_14_3_um_
filter_54_18]
PREDICTED: ankyrin
repeat domaincontaining protein 7
isoform X1
[Chlorocebus sabaeus]
GA-binding protein
subunit beta-2 isoform
X1 [Athalia rosae]
PREDICTED:
tankyrase-2
[Vollenhovia emeryi]

44%

52%

49%

52%

62%

41%

62%

36%

23%

24%

23%

29%

30%

29%

2e-06

2e-06

2e-06

2e-06

2e-06

2e-06

2e-06

WP_045105250.1

XP_020711614.1

XP_011881177.1

XP_012266656.1

XP_007980895.1

PIX03766.1

XP_011943227.1
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Tree; Chinese plum,
Japanese apricot

Tree; Peach tree

Prunus mume

Prunus persica

Tree; Jujube red
date, Chinese date,
Korean date, Indian
date
Bacteria;
Groundwater
metagenome
Plant; Saltwater
cress

Ziziphus jujuba

Armatimonadetes

Eutrema salsugineum

None

Additional Organism
Information
Synthetic ANK motif

Organism

Chain A, Crystal
Structure Of
Engineered Protein.
Northeast Structural
Genomics Consortium
Target Or265
PREDICTED: ankyrin
repeat domaincontaining protein
EMB506, chloroplastic
[Prunus mume]
ankyrin repeat domaincontaining protein
EMB506, chloroplastic
[Prunus persica]
PREDICTED: ankyrin
repeat domaincontaining protein
EMB506, chloroplastic
[Ziziphus jujuba]
hypothetical protein
AUJ92_05150
[Armatimonadetes
bacterium
CG2_30_59_28]
hypothetical protein
EUTSA_v10027842mg
[Eutrema salsugineum]

NCBI Description

17%

33%

35%

20%

20%

Query
Coverage
28%

Appendix B
Table 2. Additional alignment information from blastp results of BBB28

37%

26%

31%

38%

38%

Identity
to Query
32%

1e-04

1e-04

3e-05

1e-05

9e-06

E
value
4e-06

XP_006405540.1

OIO96820.1

XP_015895680.1

XP_007198840.2

XP_008229006.1

GenBank
Accession
4HQD_A
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Fungi; Anaerobic
gut
Animal; Japanese
spiky sea cucumber
Bacteria;
Endosymbiont of
insect Diaphorina
citri, Asian citrus
psyllid
Grass; Purple false
brome, stiff brome

Bacteria

Bacteria; Arthropod
endosymbiont
important in host
mating
incompatibility

Piromyces finnis

Wolbachia
endosymbiont of
Diaphorina citri

Bacillus sp.

Wolbachia pipientis

Brachypodium
distachyon

Apostichopus
japonicus

Synthetic ANK motif

None

Chain A, Crystal
Structure Of
Engineered Protein.
Northeast Structural
Genomics Consortium
Target Or267
ankyrin [Piromyces
finnis]
hypothetical protein
BSL78_25314
[Apostichopus
japonicus]
ankyrin repeat domaincontaining protein
[Wolbachia
endosymbiont of
Diaphorina citri]
PREDICTED: ankyrin
repeat domaincontaining protein
EMB506, chloroplastic
[Brachypodium
distachyon]
ankyrin repeat domaincontaining protein
[Bacillus sp. FJAT18017]
ankyrin repeat domaincontaining protein
[Wolbachia pipientis]
21%

18%

17%

21%

17%

34%

28%

38%

35%

36%

38%

41%

29%

30%

3e-04

3e-04

3e-04

2e-04

2e-04

2e-04

2e-04

WP_096676758.1

WP_053598089.1

XP_003564031.1

WP_017532031.1

PIK37853.1

ORX46187.1

4HB5_A
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Protozoa; Causative
agent of STD
trichomoniasis
Bacteria;
Endosymbiont of
insect Culex
molestus, London
underground
mosquito
Bacteria; Marine

Trichomonas vaginalis

Grass; Corn, maize

Synthetic ANK motif

Grass; Corn, maize
Grass; Corn, maize
Tree; Clementine
tree

Zea mays

None

Zea mays
Zea mays

Citrus clementina

Dokdonia sp.

Wolbachia
endosymbiont of Culex
molestus

Plant; Potato, Irish
potato

Solanum tuberosum

hypothetical protein
[Dokdonia sp. PRO95]
Ankyrin repeat domaincontaining protein
EMB506 chloroplastic
[Zea mays]
Chain A, Crystal
Structure Of
Engineered Protein.
Northeast Structural
Genomics Consortium
Target Or264
unknown [Zea mays]
uncharacterized protein
LOC100191181 [Zea
mays]
hypothetical protein
CICLE_v10013529mg
[Citrus clementina]

PREDICTED: ankyrin
repeat domaincontaining protein
EMB506, chloroplastic
[Solanum tuberosum]
hypothetical protein
[Trichomonas vaginalis
G3]
ankyrin repeat domain
protein [Wolbachia
endosymbiont
wPip_Mol of Culex
molestus]

17%

17%
17%

28%

17%

22%

16%

21%

17%

34%

34%
34%

28%

34%

38%

43%

39%

34%

6e-04

5e-04
5e-04

5e-04

5e-04

5e-04

4e-04

4e-04

3e-04

XP_006431025.1

ACF80469.2
NP_001130088.1

4GPM_A

AQK60863.1

WP_035333977.1

CQD12293.1

XP_001583435.1

XP_006341150.1

Appendix B
pg. 4
Bacteria; Bioreactor
metagenome

Grass; Heller’s
rosette grass,
fewanther obscure
grass, few-flowered
panic grass

Dichanthelium
oligosanthes

Grass; Sorghum,
great millet, durra,
jowari, milo
processed as food,
animal feed, and
ethanol
Animal; flatworm
found in various
aquatic/semiaquatic
environments
Bacteria;
Endosymbiont of
insect Culex
molestus, London
underground
mosquito
Insect; Emerald ash
borer

Candidatus
Amoebophilus sp.

Agrilus planipennis

Wolbachia
endosymbiont of Culex
molestus

Macrostomum lignano

Sorghum bicolor

PREDICTED: ankyrin
repeat domaincontaining protein 39like isoform X2 [Agrilus
planipennis]
hypothetical protein
BGO68_00130
[Candidatus
Amoebophilus sp. 3638]
Ankyrin repeat domaincontaining protein
EMB506, chloroplastic
[Dichanthelium
oligosanthes]

ankyrin repeat domaincontaining protein
[Wolbachia
endosymbiont of Culex
molestus]

hypothetical protein
BOX15_Mlig004077g1
[Macrostomum lignano]

ankyrin repeat domaincontaining protein
EMB506, chloroplastic
[Sorghum bicolor]

17%

25%

33%

15%

21%

17%

34%

32%

26%

45%

39%

34%

7e-04

7e-04

7e-04

7e-04

6e-04

6e-04

OEL16152.1

OJW67418.1

XP_018329392.1

WP_087740701.1

PAA47570.1

XP_002451459.1
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Wolbachia
endosymbiont of
Diaphorina citri

Wolbachia
endosymbiont of Culex
quinquefasciatus

Wolbachia
endosymbiont of Culex
pipiens molestus

Mizuhopecten
yessoensis

Wolbachia
endosymbiont of
Folsomia candida

Wolbachia
endosymbiont of Culex
pipiens

Bacteria;
Endosymbiont of
insect Culex
pipiens, Northern
house mosquito
Bacteria;
Endosymbiont of
insect Folsomia
candida, white rat
springtail
(springtails may
have been used in
biological warfare
during the Korean
War)
Animal; Japanese
scallop, Yesso
scallop, ezo giant
scallop
Bacteria;
Endosymbiont of
insect Culex
molestus, London
underground
mosquito
Bacteria;
Endosymbiont of
insect Culex
quinquefasciatus,
Southern house
mosquito
Bacteria;
Endosymbiont of
insect Diaphorina
citri, Asian citrus
psyllid
ankyrin repeat domaincontaining protein
[Wolbachia
endosymbiont of
Diaphorina citri]

ankyrin repeat domaincontaining protein
[Wolbachia
endosymbiont of Culex
quinquefasciatus]

E3 ubiquitin-protein
ligase MIB2-like
[Mizuhopecten
yessoensis]
ankyrin repeat domaincontaining protein
[Wolbachia
endosymbiont of Culex
pipiens molestus]

hypothetical protein
ASM33_07545
[Wolbachia
endosymbiont of
Folsomia candida]

ankyrin domain protein
ank12 [Wolbachia
endosymbiont of Culex
pipiens]

15%

15%

15%

20%

18%

15%

45%

45%

45%

31%

37%

45%

0.001

0.001

0.001

9e-04

8e-04

8e-04

WP_017531746.1

WP_038227557.1

WP_019078795.1

XP_021361486.1

APR99226.1

CAM59627.1
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Animal; Freshwater polyp

Bacteria;
Endosymbiont of
insect Culex
quinquefasciatus,
Southern house
mosquito
Bacteria; Causative
agent of swine
dysentery and a
spirochete
Protozoa; Causative
agent of STD
trichomoniasis
Bacteria;
Endosymbiont of
insect Folsomia
candida, white rat
springtail
Plant; Peppers,
peppers of all types

Hydra vulgaris

Wolbachia
endosymbiont of Culex
quinquefasciatus

Capsicum annuum

Wolbachia
endosymbiont of
Folsomia candida

Trichomonas vaginalis

Brachyspira
hyodysenteriae

Fish; Channel
catfish

Ictalurus punctatus

ankyrin repeat protein
[Trichomonas vaginalis
G3]
hypothetical protein
ASM33_05675
[Wolbachia
endosymbiont of
Folsomia candida]
PREDICTED: ankyrin
repeat domaincontaining protein
EMB506, chloroplastic
[Capsicum annuum]

ankyrin [Brachyspira
hyodysenteriae]

PREDICTED: acyl-CoAbinding domaincontaining protein 6
[Ictalurus punctatus]
PREDICTED:
serine/threonineprotein phosphatase 6
regulatory ankyrin
repeat subunit B-like
[Hydra vulgaris]
ankyrin repeat domain
protein [Wolbachia
endosymbiont of Culex
quinquefasciatus JHB]

17%

16%

19%

22%

15%

24%

22%

32%

38%

37%

33%

45%

33%

29%

0.002

0.002

0.002

0.002

0.002

0.001

0.001

XP_016553864.1

APR98703.1

XP_001327937.1

KLI56385.1

EEB55260.1

XP_012554050.1

XP_017322820.1
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Bacteria; Arthropod
endosymbiont
Protozoa; Causative
agent of STD
trichomoniasis
Bacteria;
Endosymbiont of
insect Nomada
flava, bee
Bacteria
Bacteria; Arthropod
endosymbiont
Bacteria;
Groundwater
metagenome
Bacteria;
Endosymbiont of
insect Culex
pipiens, Northern
house mosquito

Wolbachia

Trichomonas vaginalis

Wolbachia

Spirochaetae
bacterium

Wolbachia
endosymbiont of Culex
pipiens

Bacillus sp.

Wolbachia
endosymbiont of
Nomada flava

Mariprofundus
ferrinatatus

Bacteria;
Endosymbiont of
insect Drosophila
santomea, fruit fly
Bacteria; Marine

Wolbachia
endosymbiont of
Drosophila santomea

ankyrin domain protein
[Wolbachia
endosymbiont of
Drosophila santomea]
ankyrin repeat domaincontaining protein
[Mariprofundus
ferrinatatus]
MULTISPECIES:
hypothetical protein
[Wolbachia]
hypothetical protein
[Trichomonas vaginalis
G3]
hypothetical protein
[Wolbachia
endosymbiont of
Nomada flava]
ankyrin repeat domaincontaining protein
[Bacillus sp. EB01]
MULTISPECIES:
ankyrin repeat domaincontaining protein
[Wolbachia]
hypothetical protein
CVV51_02635
[Spirochaetae
bacterium HGWSpirochaetae-7]
ankyrin domain protein
ank12 [Wolbachia
endosymbiont of Culex
pipiens]
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Bacteria;
Endosymbiont of
insect Culex
quinquefasciatus,
Southern house
mosquito
Bacteria; Arthropod
endosymbiont
Bacteria; Amoeba
symbiont
Bacteria; Nonpathogenic, found
in various terrestrial
and aquatic
sediments
Bacteria; Adapted
to cold environment
(misleading
because it wouldn’t
survive in North
Dakota)

Wolbachia
endosymbiont of Culex
quinquefasciatus

Candidatus
Amoebophilus
asiaticus

Paenibacillus
polymyxa

Bacillus
psychrosaccharolyticus

Wolbachia

Plant; Chard, Swiss
chard

Beta vulgaris subsp.
vulgaris

hypothetical protein
[Bacillus
psychrosaccharolyticus]

MULTISPECIES:
ankyrin repeat domaincontaining protein
[Wolbachia]
hypothetical protein
[Candidatus
Amoebophilus
asiaticus]
hypothetical protein
[Paenibacillus
polymyxa]

PREDICTED: ankyrin
repeat domaincontaining protein
EMB506, chloroplastic
[Beta vulgaris subsp.
vulgaris]
ankyrin repeat domain
protein [Wolbachia
endosymbiont of Culex
quinquefasciatus Pel]
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